
Gutenberg · ebook 47767
The Propaganda for Reform in Proprietary Medicines, Vol. 2 of 2
by Council on Pharmacy and Chemistry · English · public domain in the US
Part I. THE COUNCIL ON PHARMACY AND CHEMISTRY: This section presents
the principles and rules which govern the Council in the examination of medicaments, together with articles and reports bearing on the work of the Council, and the most important reports of the Council from 1917 to April, 1922, inclusive.
Part II. THE A. M. A. CHEMICAL LABORATORY: This section, besides
presenting the aims and objects of the Association’s Chemical Laboratory, also outlines some of the Laboratory’s work which is of particular interest to physicians.
Part III. CONTRIBUTIONS FROM THE JOURNAL: Proprietary Products: This
part contains articles on proprietary medicinal preparations and the methods by which they are exploited, which have appeared in The Journal A. M. A.
Part IV. CONTRIBUTIONS FROM THE JOURNAL: MISCELLANY: In this section
are articles dealing with matters of interest to the medical profession but not coming strictly under the classification of proprietary medicinal preparations.
A comparison of the material that has appeared in Volume 1 of The Propaganda for Reform with that which appears in this volume will reveal the changing conditions in the proprietary medicine field. Many of the reports in the first volume brought out the fact that medicinal preparations were at that time foisted on the profession with false claims of composition; reports of this character are less conspicuous in the present volume. Many of the reports in Volume 2 deal with unwarranted therapeutic claims, especially those advanced for animal organ preparations, serums, vaccines, preparations for intravenous medication, etc.
The present volume will also be found of interest in its portrayal of the changed conditions in the proprietary medicine business brought about by the World War.
Special attention is directed to the index in this volume. It is, in effect, a bibliography, including references not only to articles in this book but also (1) to articles which appeared in Volume 1; (2) to articles on the same general subject in The Journal of the American Medical Association, and (3) to the articles appearing in the annual reports of the Council on Pharmacy and Chemistry and of the A. M. A. Chemical Laboratory, but not reprinted in either volume of the Propaganda for Reform in Proprietary Medicines.
PREFACE TO VOLUME 1: NINTH EDITION
From time to time The Journal of the American Medical Association has published the reports of the Council on Pharmacy and Chemistry and the Chemical Laboratory, as well as other matter on proprietary medicines.
Repeated requests for some of the matter have led to the compilation of “The Propaganda for Reform in Proprietary Medicines,” which, in the present volume, attains its ninth edition.
The seventh, eighth and ninth editions have been compiled on slightly different principles from their predecessors. The therapeutic reform work of The Journal and of the Association’s Chemical Laboratory was at first confined almost entirely to the criticism and analysis of the so-called ethical proprietaries. This was right; the medical profession owed it to the public to combat the nostrum evil within its own ranks.
As the more flagrant evils of the “ethical proprietary” question were mitigated, the Association has turned the light on the more widespread and dangerous “patent medicine” evil. The articles devoted to “patent medicines” or quackery being naturally of greater interest to the general public than to the medical profession, the number of inquiries from laymen regarding various quacks and nostrums has steadily increased.
It has been thought best, therefore, to publish separately all of the matter from The Journal relative to quackery and to those nostrums exploited only or chiefly to the public, and to include in the Propaganda for Reform practically none of the matter that is of direct interest primarily to laymen.
In one or two instances in which the subjects were of equal interest to the profession and to the public, matter that has already appeared in “Nostrums and Quackery” is also given here; but as a general rule the contents of the ninth edition of “The Propaganda for Reform” are of strictly professional interest.
Those physicians who are desirous of obtaining in convenient form the matter dealing with “patent medicines” should order the book “Nostrums and Quackery” or the various pamphlets on the same subjects that have been issued since “Nostrums and Quackery” came from the press.
The ninth edition of “Propaganda for Reform” contains a number of new articles, greatly increasing the size of the book. It also contains one novel feature which greatly enhances its value. The index includes references not only to articles in the book, but also to matter on proprietaries not accepted by the Council on Pharmacy and Chemistry which appeared in The Journal of the American Medical Association and elsewhere. This index makes of this edition of “Propaganda for Reform” a very full work of reference on proprietaries which are undeserving of recognition. It should be understood, however, that not all articles indexed are condemned; some are merely discussed and compared.
RESOLUTION ENDORSING THE WORK OF THE COUNCIL
ON PHARMACY AND CHEMISTRY
Presented at the San Francisco Session and Signed by All the Members
of the House of Delegates in Attendance
+-------------------------------------------------------------------+
| Resolved, We, Members of the House of Delegates of the American |
| Medical Association, believe that every effort must be made to |
| do away with the evils which result from the exploitation of the |
| sick for the sake of gain.
Earnestly believing that the continued |
| toleration of secret, semisecret, unscientific or untruthfully |
| advertised proprietary medicines is an evil that is inimical to |
| medical progress and to the best interest of the public, we |
| declare ourselves in sympathy with, endorse and by our best |
| efforts will further, the work which has been, and is being, done |
| by the Council on Pharmacy and Chemistry of the American Medical |
| Association in the attempt to eliminate this evil. |
+-------------------------------------------------------------------+
TABLE OF CONTENTS
PART I: COUNCIL REPORTS
PAGE
Foreword 1
Official Rules of the Council on Pharmacy and Chemistry 3
The Council on Pharmacy and Chemistry, Present and Future 12
“Accepted by the Council on Pharmacy and Chemistry” 19
Helping the Council 20
Delays in Passing on Products 20
Cooperation of the Pharmaceutical Houses 21
Budwell’s Emulsion of Cod-Liver Oil, Nos. 1 and 2 22
Rheumalgine 23
Gray’s Glycerine Tonic 24
Tongaline and Ponca Compound 26
Alfatone 28
Uricsol 30
Jubol 31
Urodonal 32
Formamint 33
Hydragogin 41
Filudine 41
Lactopeptine and Elixir Lactopeptine 43
Iodum-Miller and Iod-Izd-Oil (Miller’s) 49
Elixir Iodo-Bromide of Calcium Comp. “Without Mercury” and
“With Mercury” 52
Lecithin Preparations Omitted from N. N. R. 53
Proprietary Names for Liquid Petrolatum 55
Seng 55
Frosst’s Blaud Capsules 56
Tyree’s Elixir of Buchu and Hyoscyamus Compound 57
Hydroleine 58
Curative Vaccine, Bruschettini 58
Stearn’s Wine 59
Protonuclein and Protonuclein Beta 59
Hydropsin 61
Digitalysatum 63
So-Called Secretin Preparations 64
Has Secretin a Therapeutic Value? 65
Radio-Rem 79
Olio-Phlogosis 79
The Hypophosphite Fallacy 80
Pulvoids Calcylates 85
Sulfuryl Monal 86
Mark White Goiter Serum and Mark White Iodinized Oil 87
Kora-Konia 92
The Therapeutic Value of the Glycerophosphates 93
Hydras 96
Bromin-Iodin Compound 97
Ammonium Hypophosphite Omitted from N. N. R. 98
Alphozone Omitted from N. N. R. 99
Calcium Glycerophosphate and Sodium Glycerophosphate Omitted
from N. N. R. 99
Gardner’s Syrup of Ammonium Hypophosphite Omitted
from N. N. R. 100
Gluten Products Made by the Kellogg Food Company 100
Iodo-Mangan Omitted from N. N. R. 106
Liquid Albolene 106
Naphey’s Medicated Uterine Wafers 107
Nujol 108
Pulvoids Natrium Compound 108
Saloform 110
Secretogen 110
Iron Citrate Green 115
Aspirin 116
Pil. Cascara Compound-Robins 117
Casta-Flora 118
Firwein 119
Firolyptol Plain and Firolyptol with Kreosote 120
Biniodol 121
Comparative Symptoms Resulting from the Use of Several Oily
Suspensions of Red Mercuric Iodid (Mercury Biniodid) 123
Corpora Lutea (Soluble Extract), Parke, Davis & Co. 128
Wheeler’s Tissue Phosphates 129
The Claimed Galactagogue Effects of Nutrolactis and
Goat’s Rue Not Substantiated 131
The Alleged Galactagogue Action of Galega and Nutrolactis 131
The Russell Emulsion and the Russell Prepared Green Bone 134
Brom-I-Phos 136
Creosote-Delson and Creofos 137
Triner’s American Elixir of Bitter Wine 139
Trimethol 140
Ferrivine, Intramine and Collosol Iodine 144
Eskay’s Neuro Phosphates 146
K-Y Lubricating Jelly 147
Ziratol 148
Gonosan 150
Alcresta Ipecac 153
Iodeol and Iodagol 154
Capsules Bismuth Resorcinol Compound Not Admitted to N. N. R. 157
Dixon’s Tubercle Bacilli Extract and Dixon’s Suspension of
Dead Tubercle Bacilli 158
Formosol 158
Iodolene, a Solution of Iodin in Liquid Petrolatum,
Inadmissible to N. N. R. 159
Kalak Water 160
Minson’s Soluble Iodin “Kelpidine” Not Admitted to N. N. R. 161
Nutone 162
Tri-Arsenole, L. O. Compound No. 1 and L. O. Compound No. 2 163
Unctol 166
V-E-M (Schoonmaker Laboratories, Inc.) 166
Hemo-Therapin 168
Venosal 169
Secretin-Beveridge and the U. S. Patent Law 170
The Question of the Stability of Secretin 171
Need for Patent Law Revision 177
Surgodine 180
Medeol Suppositories 181
Guaiodine 183
Several “Mixed” Vaccines Not Admitted to N. N. R. 184
Ophthalmol-Lindemann 189
Silvol Ineligible for N.N.R 189
Katharmon 191
Iodinized Emulsion (Scott) and Creosotonic (Scott) 192
Campetrodin and Campetrodin No. 2 193
Carminzym 194
Phillips’ Phospho-Muriate of Quinine Comp 197
B. Iodine and B. Oleum Iodine 198
B. Iodine Products 199
Antithyroid Preparations (Antithyroidin-Moebius and
Thyreoidectin) Omitted from N. N. R. 202
Cephaelin and Syrup Cephaelin-Lilly Omitted from N. N. R.
and Syrup Emetic-Lilly Not Accepted 203
Colalin Omitted from N. N. R. 203
Foral 204
Granular Effervescent Bromide and Acetanilid Compound-Mulford 206
Holadin and Bile Salt Mixtures 207
Liquor Santaiva, S. & D., Omitted from N. N. R. 211
Maltzyme, Maltzyme with Cascara Sagrada, Maltzyme with Cod
Liver Oil, Maltzyme Ferrated and Maltzyme with Yerba Santa
Omitted from N. N. R. 211
Methaform Omitted from N. N. R. 212
Pineal Gland, Red Bone-Marrow and Thymus Gland and Their
Preparations Omitted from N. N. R. 213
Piperazine and Lycetol Omitted from N. N. R. 214
Stanolind Liquid Paraffin Omitted from N. N. R. 214
Westerfield’s Digitalis Tablets 215
Xeroform-Heyden and Bismuth Tribromphenate-Merck Omitted
from N. N. R. 216
Cream of Mustard Refused Recognition 218
“Pluriglandular” Mixtures 218
Cerelene Not Admitted to N. N. R. 219
Collosol Cocaine Not Admitted to N. N. R. 221
Cuprase Not Admitted to N. N. R. 222
Collosol Preparations 223
Pulvoids Calcylates Compound 226
Proteogens of the Wm. S. Merrell Company 227
“Arsenoven S. S.” and “Arseno-Meth-Hyd” 231
Hormotone and Hormotone Without Post-Pituitary 234
Formaldehyde Lozenges 235
Lavoris 237
Medinal 239
Omission of Cotarnin Salts (Stypticin and Styptol)
from N. N. R. 240
Micajah’s Wafers and Micajah’s Suppositories 241
Alkalithia 242
Arhovin Omitted from N. N. R. 243
Chloron, Chlorax and Number “3” 244
Elarson Omitted from N. N. R. 248
Iodiphos 249
Mervenol and Armervenol Not Admitted to N. N. R. 249
Normal Phenol Serum (Cano) and Methyl-Phenol Serum (Cano)
Not Accepted for N. N. R. 251
Soamin Omitted from N. N. R. 253
Some Mixed Vaccines Not Admitted to N. N. R. 254
Somnoform 255
Tablets Formothalates 256
Triple Arsenates with Nuclein 256
“Anti-Pneumococcic Oil” and the Use of Camphor in Pneumonia 257
Dial “Ciba” 259
Apothesine 260
Eumictine 262
Platt’s Chlorides 263
Anti-Tuberculous Lymph Compound (Sweeny) and Anti-Syphilitic
Compound (Sweeny) 266
Syrup Leptinol (Formerly Syrup Balsamea) 268
Formitol Tablets, II 271
Sukro-Serum and Aphlegmatol 273
Supsalvs Not Admitted to N. N. R. 274
Hypodermic Solution No. 13, Iron, Arsenic and Phosphorus
Compound Not Accepted for N. N. R. 275
Parathesin Not Admitted to N. N. R. 276
Chlorlyptus 277
Aquazone (Oxygen Water) 290
Coagulen-Ciba Omitted from N. N. R. 290
Ferric Cacodylate Omitted from New and Non-Official Remedies 292
Libradol 293
Helmitol Omitted from N. N. R. 295
Spirocide Not Admitted to N. N. R. 296
Digifolin-Ciba Not Admitted to N. N. R. 298
Some of Loesser’s Intravenous Solutions 299
“National Iodine Solution” Not Admitted to N. N. R. 300
Mon-Arsone Not Admitted to N. N. R. 302
Oxyl-Iodide Not Admitted to N. N. R. 304
Quassia Compound Tablets 306
Toxicide 307
Pil. Mixed Treatment (Chichester) 310
Atophan Omitted from N. N. R. 313
Urotropin Omitted from N. N. R. 316
Styptysate Not Admitted to N. N. R. 318
Lipoidal Substances (Horovitz) Not Admitted to N. N. R. 320
Yeast Preparations and Vitamin B Concentrates 321
PART II: CONTRIBUTIONS FROM THE A. M. A. CHEMICAL LABORATORY
The Chemical Laboratory of the American Medical Association 322
The Work of the American Medical Association Chemical
Laboratory 322
Lead in “Akoz” 328
Sodium Acetate in Warming Bottles 329
Anti-Syphilitic Compound (Sweeny) 330
“Ambrine” and Paraffin Films 330
The Stability of Iodine Ointments 337
Iodolene and the Solubility of Iodin in Liquid Petrolatum 344
American-Made Synthetic Drugs--I 344
Standardization of Commercial Bismuth Tribromphenate 348
Standardization of Procain and Examination of the
Market Supply 355
Deterioration of Sodium Hypochlorite Solutions 358
Syphilodol 359
Cerelene 362
Dr. De Sanctis’ Rheumatic and Gout Pills 363
Iodex and Liquid Iodex 365
PART III: CONTRIBUTIONS FROM THE JOURNAL: PROPRIETARY PRODUCTS
Iodin in Liquid Petrolatum 367
American-Made Synthetic Drugs--II 369
Nostrums in Retrospect 379
Bell-Ans (Pa-Pay-Ans Bell) 380
Anasarcin and Anedemin 383
Pepto-Mangan 387
Cactina Pillets 391
Ammonol and Phenalgin 393
Fellows’ Syrup, and Other Preparations of the Hypophosphites 395
Shotgun Nostrums 398
Tyree’s Antiseptic and Aseptinol 401
Neurosine and the Original Package Evil 404
Anasarcin Advertising 407
Antimeristem-Schmidt 408
Antiphlogistine 409
“Auto-Hemic Serum” 409
“Autolysin” Advertising 413
“Basic Cancer Research” and “Cosmopolitan Cancer Research
Society” 414
Seleni-Bascca 416
Bell-Ans (Papayans, Bell) 418
Campho-Phenique 418
“Cinchophen”: Formerly “Atophan” 419
“Collosols”: An Uncritical English Endorsement 420
Cotton Process Ether 421
Dionol 422
The Eli Products of Eli H. Dunn 424
Glover’s Cancer Serum 425
Glyco-Thymoline and Poliomyelitis 427
Glykeron: Cold Storage Testimonials 428
Gray’s Glycerine Tonic: “Whose Bread I Eat His Song I Sing” 429
Hagee’s Cordial of Cod Liver Oil 429
Hypno-Bromic Compound 430
Intravenous Compound (Loffler) 430
Intravenous Specialties 435
Iodex 436
The William F. Koch Cancer Remedy 437
The Lucas Laboratories’ Products 440
“Phylacogens” 441
Pineoleum Advertising Methods 442
“Proteal Therapy” and Henry Smith Williams 443
Proteogens 445
Pulvane 450
Sal Hepatica 451
Salicon 453
So-Called Secretin Preparations 454
Succus Cineraria Maritima 455
Tekarkin 458
Tyree’s Antiseptic Powder Again 462
Wheeler’s Tissue Phosphates 463
Briefer Paragraphs 465
PART IV: CONTRIBUTIONS FROM THE JOURNAL: MISCELLANY
Albert Abrams, A.M., M.D., LL.D., F.R.M.S. 472
Acetylsalicylic Acid, Not Aspirin 480
The Allied Medical Associations of America 486
“Arsenicals” 491
Beer and Cancer Cures 494
Biologic Therapeutics and Its Commercial Domination 496
Capell’s Uroluetic Test 497
Chemotherapy and Tumors 499
The Direct Sales Company 510
Discoveries and Discoverers 511
“Drug Reform” 513
Drug Therapy: The Fallibility of Textbooks 515
Thomas Webster Edgar 515
Glycerophosphates 520
Influenza Vaccine 520
Intravenous Therapy 522
Iodin Fumes 523
Italian Physico-Chemical Company 524
What is Liquid Petrolatum? 526
The Lowenthal Postgraduate Course 527
Medical Society of the United States 531
The National Formulary--A Review of the Fourth Edition 535
Nonspecific Protein Therapy 536
Willard Ealon Ogden 538
“Patents” 542
Pharmaceutical Barnums 545
The Pharmacopeia 546
Physician’s Stock in Prescription Products 548
Pituitary Gland Preparations 549
Proprietorship in Medicine 550
Philip Rahtjen and His Discoveries 553
Sodium Cacodylate in Syphilis 555
Tablets: Dependability of Dosage 556
Therapeutic Evidence: Its Crucial Test 557
“Vaccines in Toxic Conditions” 560
Vitamins: Their Distribution 561
The William A. Webster Co. and the Direct Pharmaceutical Co. 564
Yeast 566
Briefer Paragraphs 570
THE PROPAGANDA FOR REFORM IN PROPRIETARY MEDICINES
PART I
REPORTS OF THE COUNCIL ON PHARMACY AND CHEMISTRY
FOREWORD
THE COUNCIL ON PHARMACY AND CHEMISTRY
The Council on Pharmacy and Chemistry was established by the American Medical Association primarily for the purpose of gathering and disseminating such information as would protect the medical profession--and thus the public--in the prescribing of proprietary medicinal articles.
The Council consists of sixteen members, fifteen appointed for a term of five years without pay, and the sixteenth, a secretary, who is also the director of the Chemical Laboratory of the American Medical Association (see Part II).
At the present time (1921) the membership is:
C. L. Alsberg, A.M., M.D., Chief of the Bureau of Chemistry, U. S.
Department of Agriculture, Washington, D. C.
C. W. Edmunds, M.D., Professor of Materia Medica and Therapeutics,
University of Michigan Medical School, Ann Arbor.
R. A. Hatcher, Ph.G., M.D., Professor of Pharmacology, Cornell
University Medical College, New York City.
A. W. Hewlett, M.D., Professor of Medicine, Leland Stanford Junior
University School of Medicine, San Francisco.
John Howland, M.D., Professor of Pediatrics, Johns Hopkins University
Medical Department, Baltimore.
Reid Hunt, M.D., Professor of Pharmacology, Medical School, Harvard
University, Boston.
W. T. Longcope, A.B., M.D., New York.
G. W. McCoy, M.D., Director of the Hygienic Laboratory, U. S. Public
Health Service, Washington, D. C.
Lafayette B. Mendel, Ph.D., Sc.D., Professor of Physiological
Chemistry, Sheffield Scientific School, Yale University, New Haven.
F. G. Novy, Sc.D., M.D., Professor of Bacteriology, University of
Michigan Medical School, Ann Arbor.
W. W. Palmer, B.S., M.D., Bard Professor of Medicine, Columbia
University College of Physicians and Surgeons, New York.
W. A. Puckner, Phar.D., Secretary of the Council, Director of the
Chemical Laboratory of the American Medical Association, Chicago.
L. G. Rowntree, M.D., Sc.D., Professor of Medicine, Mayo Foundation,
Rochester.
G. H. Simmons, M.D., LL.D., Chairman of the Council, Editor of The
Journal of the American Medical Association, Chicago.
Torald Sollmann, M.D., Professor of Pharmacology and Materia Medica,
Western Reserve University School of Medicine, Cleveland.
Julius Stieglitz, Ph.D., Sc.D., Chem.D., Professor of Chemistry,
University of Chicago, Vice-Chairman of the Council, Chicago.
At its first meeting in 1905, the Council began examining the proprietary and nonofficial medicinal preparations offered to physicians of the United States, and authorized the publication of a book (New and Nonofficial Remedies) containing descriptions of those preparations which were deemed worthy of the consideration of physicians. It also issued reports (Reports of the Council on Pharmacy and Chemistry) to the medical profession on those preparations which were not eligible.
The Council adopted a set of rules by which to measure the eligibility of each preparation for admission to New and Nonofficial Remedies. These rules were designed primarily to protect the public--through the medical profession--against fraud, undesirable secrecy and objectionable advertising in connection with proprietary medicinal articles. The rules originally adopted have been subjected to revision from time to time to meet changing conditions.
For the information of those who wish to familiarize themselves with the work of the Council the rules which are now in force (1921) follow this introduction. A summary is also to be found in the article, “The Work of the Council on Pharmacy and Chemistry, Present and Future,” page 12.
Since 1906, the Council has issued New and Nonofficial Remedies annually. In each issue are listed and described the articles that stand accepted on January 1 of the year of publication. The book describes proprietary medicinal articles on the American market that are found eligible under the rules, and also such nonproprietary, nonofficial articles as give promise of therapeutic usefulness, listing the acceptable brands. Articles of a similar character are grouped together, and each group is preceded by a general discussion for the purpose of comparison.
Since 1908, the Council has also issued an annual volume, “Reports of the Council on Pharmacy and Chemistry,” which contains reports on proprietary medicines that were found inadmissible to New and Nonofficial Remedies. The reports issued prior to 1916--and deemed of sufficient interest to physicians--were reprinted in the Propaganda for Reform in Proprietary Medicines, ninth edition (1916). The more important reports issued from 1916 to 1921, inclusive, are in this volume.
While it is the chief function of the Council to investigate and report on proprietary medicinal preparations, its work has broadened so that the Council’s work may now be characterized as a propaganda for the rational use of drugs. Thus, its Committee on Therapeutic Research encourages the investigation of questions concerning the actions of drugs.
These investigations are brought together in the “Annual Reports of the Therapeutic Research Committee.” The Council also has a committee on medical teaching which has issued the publication “Useful Drugs,” a concise, but thorough and up-to-date, discussion of the more important drugs. In addition, the Council appointed a committee to prepare an “Epitome of the U. S.
Pharmacopeia and National Formulary,” in which are presented those portions of the United States Pharmacopeia and the National Formulary that are of interest to physicians and in which is given a concise statement of the therapeutic usefulness of such drugs and preparations.
OFFICIAL RULES OF THE COUNCIL ON PHARMACY AND CHEMISTRY
[May 1, 1921]
Introduction
The following rules have been adopted by the Council primarily with the object of protecting the medical profession and the public against fraud, undesirable secrecy and objectionable advertising in connection with proprietary medicinal articles.
NEW AND NONOFFICIAL REMEDIES.--The book New and Nonofficial Remedies contains a description of proprietary articles which have been accepted as conforming to the rules of the Council; and of such simple nonproprietary and nonofficial substances as seem of sufficient importance to warrant their inclusion.
MIXTURES.--For admission to N. N. R., proprietary pharmaceutical mixtures must comply with the rules; and, to determine such compliance, they will be investigated by the Council. The Council, however, endorses the principle that prescriptions should be written on the basis of the therapeutic effects of the individual ingredients. For this reason, it includes in this book only those mixtures that present some real advantage. There is also an appendix in which are included those proprietary articles which, so far as known to the Council, comply with the rules, but which do not possess sufficient originality to be admitted to the body of the book.
Rules Governing the Admission of Proprietary Articles to the Book
New and Nonofficial Remedies
DEFINITION OF PROPRIETARY ARTICLES.--The term “proprietary article,” in this place, shall mean any chemical, drug or similar preparation used in the treatment of diseases, if such article is protected against free competition, as to name, product, composition or process of manufacture, by secrecy, patent, copyright, or by any other means.
Rule 1.--COMPOSITION.--No article will be accepted for inclusion in the book New and Nonofficial Remedies, or retained therein, unless its composition be furnished to the Council for publication. For simple substances, the scientific name and the chemical formula, rational or structural, if known, should be supplied. For mixtures, the amount of each active medicinal ingredient in a given quantity of the article must be stated. The general composition of the vehicle, its alcoholic percentage, and the identity of the preservatives must be furnished.
Rule 2.--IDENTIFICATION.--No article will be accepted or retained unless suitable tests for determining its composition are furnished to the Council. In the case of chemical compounds, these shall consist of tests for identity and purity. In the case of mixtures, description of methods for determining the amount and active strength of the potent ingredients shall be furnished, if practicable.
Rule 3.--DIRECT ADVERTISING.--No article that is advertised to the public will be accepted or retained; but this rule shall not apply to: (a) disinfectants, germicides and antiseptics, provided the advertising is limited to conservative recommendations for their use as prophylactic applications to superficial cuts and abrasions of the skin and to the mucous surfaces of the mouth, pharynx and nose (but not to those of the eye, and the gastro-intestinal and genito-urinary tracts) and provided they are not advertised as curative agents (see comments to Rule 3); and (b) nonmedicinal food preparations, except when advertised in an objectionable manner.
Rule 4.--INDIRECT ADVERTISING.--No article will be accepted or retained if the label, package or circular accompanying the package contains the names of diseases in the treatment of which the article is said to be indicated. The therapeutic indications and properties may be stated, provided such statements do not suggest self-medication. Dosage may be indicated. (This rule shall not apply to remedies with which self-medication is altogether improbable, to vaccines and antitoxins or to directions for administering or applying remedies when similar immediate, heroic treatment is indicated.)
Rule 5.--FALSE CLAIMS AS TO ORIGIN.--No article will be accepted or retained concerning which the manufacturer or his agents make false or misleading statements as to source, raw material from which made, or method of collection or preparation.
Rule 6.--UNWARRANTED THERAPEUTIC CLAIMS.--No article will be accepted or retained concerning which the manufacturer or his agents make unwarranted, exaggerated or misleading statements as to the therapeutic value.
Rule 7.--POISONOUS SUBSTANCES.--The principal label on an article containing “poisonous” or “potent” substances must state plainly the amount of each of such ingredients in a given quantity of the product.
Rule 8.--OBJECTIONABLE NAMES.--Proprietary names for medicinal articles will be recognized only when the Council shall deem the use of such exclusive names to be in the interest of public welfare. Names which are misleading or which suggest diseases, pathologic conditions or therapeutic indications will not be recognized (the provision against therapeutically suggestive names does not apply to serums, vaccines and antitoxins, or to foods). In the case of pharmaceutical preparations or mixtures, the name must be so framed as to indicate the most potent ingredients.
Rule 9.--PATENTED PRODUCTS AND PROTECTED NAMES.--If the article is patented--either process or product, or both--the number of such patent or patents must be furnished to the Council. Furthermore, if the name of an article is registered, or the label copyrighted, the registration (trademark) number and a copy of the protected label should be furnished the Council. In case of registration in foreign countries, the name under which the article is registered should be supplied.
Rule 10.--UNSCIENTIFIC AND USELESS ARTICLES.--No article will be accepted or retained which, because of its unscientific composition, is useless or inimical to the best interests of the public or of the medical profession.
Explanatory Comments on the Rules
INTRODUCTION.--The Council on Pharmacy and Chemistry was established in February, 1905, by the American Medical Association, primarily for the purpose of gathering and disseminating such information as will protect the medical profession in the prescribing of proprietary medicinal articles. In pursuance of this object, the Council examines the articles on the market as to their compliance with definite rules designed to prevent fraud, undesirable secrecy and the abuses which arise from advertising directly or indirectly to the laity.
Such articles as appear to conform to the rules are accepted; and their essential features are described in the annual publication of the Council, New and Nonofficial Remedies, if they come within the scope of this book. These descriptions are based in part on investigations made by, or under, the direction of the Council, but in part also on evidence or information supplied by the manufacturer or his agents.
Such interested statements are examined critically, and are admitted only if they appear to be in conformity with the evidence. It is, however, manifestly impossible for the Council to investigate the composition of every complex pharmaceutical mixture, or to check thoroughly every therapeutic claim; it can give only an unbiased judgment on the available evidence. Criticisms and corrections of the descriptions which may aid in the revision of the matter will be appreciated. The Council judges an article entirely by the facts in evidence at the time of its admission.
Previous noncompliance with the rules (short of intentional fraud) does not prevent the favorable consideration of an article which is in accord with existing rules.
Infringements of the rules after acceptance of an article for New and Nonofficial Remedies, or the discovery that the Council’s information was incorrect, will cause the acceptance to be reconsidered. An article is accepted for New and Nonofficial Remedies, and will continue to be included in the book, with the understanding that serious violations of the rules, after acceptance, will be followed by the omission of the article and publication of the reasons for such omission. The Council desires physicians to understand that the admission of an article does not imply a recommendation. Acceptance simply means that no conflict with the rules has been found by the Council.
DURATION OF ACCEPTANCE.--Unless an agreement to the contrary is made at the time of acceptance, articles admitted to New and Nonofficial Remedies will be retained for a period of three years, provided that during that period they comply with the rules and regulations which were in force at the time of their acceptance. At the end of this period all articles will be carefully reexamined for compliance with existing rules.
Particular weight will be given to the question as to whether recent evidence has substantiated claims as to the therapeutic value of any preparation, this evidence to consist partly of recent statements in the literature and partly of the general esteem in which the preparation is held by clinical consultants of the Council. The reacceptance of articles after such reexamination shall be for three years unless a shorter period is specified.
Any amendments to the rules, by specific requirements or by interpretation, which may be made after the acceptance of an article, shall not apply to such article until the period of acceptance has elapsed. At the end of this period the article, if it is not eligible under the amended rules, will be omitted.
THE SCOPE OF NEW AND NONOFFICIAL REMEDIES AND APPENDIX.--To aid
physicians and manufacturers in deciding what articles come within the scope of this book, or, in other words, to enable physicians to recognize whether an article which is not described in New and Nonofficial Remedies has been omitted because it does not need admission or because it has been rejected, the Council furnishes the following more detailed definitions:
OFFICIAL ARTICLES.--Articles official in the U. S. P. or N. F. do not require consideration by the Council if they are marketed under the official name and if no unestablished therapeutic claims are made for them.
These do not require consideration by the Council, since standards for them are provided in these books, and enforced under the provisions of the federal Food and Drugs Act, except that they may be mentioned for information. Consideration by the Council becomes necessary if a U. S. P. or N. F. product is offered for sale under a name other than that, or the synonyms, under which the product is described in one of these books of standards, or if the proprietors or their agents advance claims that the product possesses therapeutic properties other than those commonly accredited to it.
MODIFICATIONS OF U. S. P. AND N. F. PRODUCTS.--A pharmacopeial or National Formulary product which is marketed under the official title or synonym, but with well-founded claims that its purity, permanence, palatability or other physical properties excel the official standard, may, if no extraordinary therapeutic properties are asserted, be considered as an official article and held not to be within the scope of New and Nonofficial Remedies. When such products are marketed under the claim that they possess therapeutic properties other than those commonly accredited to the U. S. P. or N. F. products of which they are modifications, they shall be subject to the consideration of the Council.
SPECIFICALLY EXEMPTED PREPARATIONS.--Foods, in general, unless marketed with the claim that they possess therapeutic properties shall not, at the present time, be considered by the Council. Mechanical appliances, at the present time, shall not be considered by the Council. Mineral waters (natural), at the present time, shall not be considered by the Council. With these exceptions, products which in the judgment of the Council are manufactured and marketed in conformity to the principles underlying the rules of the Council may be accepted for N. N. R.
Products which are manufactured and marketed in a manner which does not conform to the principles underlying the rules of the Council shall not be accepted for N. N. R. The burden of proof in establishing claims for therapeutic properties of products considered by the Council shall lie with the proprietor or, when a foreign made product, with the agent who markets the product in the United States. To avoid confusion with nonofficial substances marketed under similar names, the Council recommends that official substances be prescribed by their official titles, followed by the abbreviation “U. S. P.” or “N. F.”; thus:
Tinctura Nucis Vomicae, U. S. P.; Elixir Gentianae, N. F.
SUBSTANCES DESCRIBED IN NEW AND NONOFFICIAL REMEDIES.--In the body of
the book will be described simple proprietary substances and their preparations; proprietary mixtures if they have originality or other important qualities which, in the judgment of the Council, entitle them to such place, and important, nonproprietary, unofficial articles.
The Council recommends that when the latter are prescribed, they be indicated by the abbreviation, “N. N. R.,” thus insuring to the prescriber the quality of these articles laid down in the book.
PROPRIETARY MIXTURES.--A mixture will be considered as proprietary, and therefore requiring consideration by the Council for admission to the book or appendix, if it contains any proprietary article; if it is marketed under a name which is in any way protected, or if its manufacturer claims for it any unusual therapeutic qualities.
Proprietary mixtures which are marketed in conformity with the rules are listed in the appendix of the book under the names of the respective manufacturers. Such proprietary mixtures are not admitted to the body of the book, save in the exceptional cases cited in the preceding paragraph.
NONPROPRIETARY MIXTURES OF OFFICIAL SUBSTANCES.--Since the ingredients of such mixtures do not require consideration by the Council, and since the mixtures are not open to the proprietary abuses which call for the work of the Council, it is not necessary that they should be investigated by the Council. The physician must judge whether such mixtures should be directed to be prepared by the pharmacist, or whether he is justified in ordering a ready-made preparation. If he decides to use a ready-made, nonproprietary preparation, he must judge for himself whether it is marketed in accordance with the rules.
It should, however, be remembered that the application of a trade name to any substance makes it proprietary.
Explanation of Rule 1: Composition
Secrecy Objectionable.--It is not only the right but also the duty of the physician to know the essential composition of what he prescribes; the Council cannot compromise on this proposition.
Vehicles and Preservatives.--In the case of mixtures, not only the potent ingredient, but also the general character of the vehicle, the presence of alcohol, and the identity of preservatives, or of any other substance, whether added or present as an impurity, must be stated if these can under any circumstances affect the therapeutic action of the article. This, as a rule, does not mean the publication of trade secrets, such as flavors or the details of the working formula.
Trade Secrets.--Furthermore, trade secrets will not be received as confidential by the Council, since it accepts information only with the distinct understanding that this may be freely published, at its discretion.
Inspection of Factories.--The Council does not accept invitations to inspect factories; its concern is with the finished products.
On the other hand, the Council requires that the information be complete and accurate as to medicinal ingredients.
Unofficial Constituents.--Unofficial constituents of proprietary mixtures must be presented by the manufacturer in the regular way and must be acted on by the Council before the preparations containing them can be accepted.
Fraud.--When it appears that a manufacturer has made a deliberately false statement concerning a product, he is asked to furnish an explanation; and if this is not satisfactory, the product will not be accepted, even if the false statement is subsequently corrected or omitted.
Testimonials.--The foregoing paragraph applies not only to statements made to the Council, but also to statements furnished to physicians by the manufacturer or his agents, even when these statements are in the guise of testimonials.
Explanation of Rule 2: Identification
In order to avoid errors in the case of chemical compounds, and to guard against adulterations, lack of potency or strength, and the mistaking of one chemical for another, it is necessary to have at hand suitable tests.
Tests, etc.--If these facts have appeared in the literature, or in standard textbooks, reference to them will be sufficient; but with new chemicals, especially synthetics, the manufacturer or his representatives will be required to supply such tests for publication, as will assure an intelligent opinion of these products.
Physiologic Standardization.--In cases in which chemical methods of identification are unknown or unreliable, physiologic standardization should be employed. The Council considers the phrase “physiologically standardized” or “assayed” as misleading unless the standard and method are published in sufficient detail to permit of their control by independent investigators.
It is evident that when no standard is published, it is impossible to know whether the quality is high or low, and the conscientious manufacturer who sets for himself a high standard is placed on a level with the dishonest or careless one who adopts a low standard. Again, if the process of standardization is not published, it is impossible to learn, without actual trial, the relative value of one preparation as compared with that of another manufacturer, or to confirm or disprove the statements of the manufacturer as to the quality of his product.
Standardization of Disinfectants and Germicides.--No disinfectant or germicide of the phenol type will be accepted for New and Nonofficial Remedies whose phenol coefficient, determined according to the method of the Hygienic Laboratory, U. S. P. H. S., is not stated on the label of the preparation.
Explanation of Rule 3: Direct Advertising
Lay Advertising.--The impossibility of controlling the irresponsible claims which are usually made in advertisements to the public, the well-known dangers of suggesting by descriptions of symptoms to the minds of the people that they are suffering from the many diseases described, the dangers of the unconscious and innocent formation of a drug habit, and the evils of harmful self-medication, including the dangers of the spread of many infectious and contagious diseases when hidden from the physician, and similar well-known considerations, are the reasons for discouraging, in the interest, and for the safety, of the public, this reprehensible form of exploitation.
Advertising in medical journals, etc., distributed solely to physicians, does not come within the scope of this rule.
Exceptions.--In the case of subjects on which the public should be instructed, as the use of disinfectants, germicides, antiseptics and foods, advertisements to the public, if not in objectionable forms, are considered admissible. In no case shall such advertisements include recommendations for use as curative agents, nor shall the names of any diseases be mentioned in exploitation. If the preparation is sufficiently toxic to require caution in its use to prevent poisoning, this fact shall be stated on the label.
On account of the deplorable results which would follow any abuse of this privilege, the conscientious cooperation of manufacturers and their agents in adhering strictly to the limitations laid down is asked; and for the same reason the acceptance of an article which is so advertised as to infringe on these limitations in any essential way (as by naming diseases or by making false and exaggerated claims) shall be summarily rescinded, and the reasons for such action may be published without notice to manufacturer or agent.
A disinfectant, germicide or antiseptic will be accepted for description in New and Nonofficial Remedies, and an article of this class which has already been accepted will continue to be included in New and Nonofficial Remedies only on the explicit understanding by the manufacturer and agent that such infringements of the rule will be followed by deletion of the article and by publication of the facts as described.
Foods.--We may divide the foods into three groups. The first group contains the ordinary foods, including the well-known breakfast foods. These do not come under the supervision of the Council in any way. The second group includes a large and important class of manufactured products, such as invalid and infant foods, which in a sense stand between the first and third groups. The public has the same interest in these foods that the physician has, and usually is supplied with full information concerning them.
While the primary recommendation of these articles should naturally come from the physician, it cannot be expected that their continued use should depend on repeated prescriptions. Information concerning this group of foods would come naturally and properly from a physician, and the collection and dissemination of this information may very properly be included in the work of this Council.
As the products in this class are used extensively, it is not proper to limit their advertising to medical journals, but the advertising should be permitted in the lay press so long as it is conducted in a manner compatible with the rules of the Council. The third group includes medicinal foods proper, such as predigested foods. These have a relatively low food value and are characterized by a high alcohol or preservative content.
They frequently contain strictly medicinal substances, or food substances for which distinct therapeutic properties are claimed.
These products should be used only on the advice of the physician, and the advertisements should be restricted as in the case of ordinary medicines.
Advertisements in Foreign Countries.--The Council deals primarily, in the interest of the public and of the medical profession, with articles proposed for admission to New and Nonofficial Remedies, and, in determining the status of any article, must take into consideration any statements made regarding it or any method of advertising it employed by the manufacturer or his authorized agents or representatives, whether in this country or abroad.
The Council will not regard as within its scope, however, questions concerning the marketing of articles (except the matter of direct advertising to the laity and unwarranted claims or misrepresentations) in any country which has a public body corresponding to this Council.
Explanation of Rule 4: Indirect Advertising
Matter Distributed Solely to Physicians.--It should be remembered that the sole intent of this rule is to protect the physician, so that in prescribing a proprietary medicine he shall not unconsciously advertise proprietary preparations. The rule imposes no restriction on the legitimate methods of bringing a remedy to the attention of the profession, such as advertising in medical journals, circulars and other printed matter distributed solely to physicians. The rule applies only to the package as it may reach the patient.
Naming Diseases on Labels.--The naming of diseases on the label or package is not necessary, as is shown by the very large number of proprietary products which have been successfully introduced without resorting to this expedient. This method of popularizing a proprietary remedy with the laity is most objectionable, and should not be tolerated in any form. In general, therapeutic indications should be omitted from the label and package.
The Council will not insist on this point, however, when such indications are so given as not to promote self-medication, particularly in diseases which require expert diagnosis and supervision. It will be considered an infringement of the rule if an article be marketed in bottles which have the name of the article blown into the glass, or if otherwise the name or initials or other distinctive mark of the article is permanently stamped on the container, on the article itself, or is on the stoppers or seals.
Articles which are marketed in any of these ways are not accepted for New and Nonofficial Remedies. Readily removable labels are not objectionable, nor is the permanent affixing of the firm’s initials or name to the trade package if such initials or name is not suggestive of the article. The Council does not countenance the use of an accepted article for advertising other articles which have not been accepted by the Council.
Explanation of Rule 5: False Claims as to Origin
Source.--No false or misleading statement in regard to an article can be permitted concerning the source of material from which it is made, or the persons by whom it is made. Some glaring frauds of this nature have been perpetrated in the past, and this rule is intended to prevent such imposition.
Explanation of Rule 6: Unwarranted Therapeutic Claims
Therapeutic Questions.--This rule insists that the claims of manufacturers or agents concerning the therapeutic properties of their products must be compatible with demonstrable facts. Manufacturers will be held responsible for all statements made or quoted in their advertising “literature” regarding their products. Recognizing the existence of honest differences of opinion on many therapeutic questions, the Council desires to be liberal in the application of this rule. It is natural that a manufacturer should be partial toward his own product, and a moderate degree of emphasis in advertising may not be objectionable.
The Council, however, will not admit claims which are neither in harmony with already accepted facts nor supported by acceptable evidence. In doubtful cases the Council considers these questions with the advice and cooperation of its staff of clinical consultants.
Clinical Evidence.--To be acceptable, the clinical evidence must offer objective data with such citation of authority as will enable the Council to confirm the facts and establish the scientific value of the conclusions drawn. Clinical data are worthless when the author is not cited. The facts on which claims with regard to the value of a remedy are based must have been rendered accessible for investigation and confirmation by disinterested observers, either through publication or through the records of a hospital or other institution.
Explanation of Rule 7: Poisonous Substances
Poisons.--For the information of the pharmacist or dispenser, and to enable him to safeguard the interests of the patient and the physician, all articles containing such potent agents as the poisonous alkaloids and other organic substances and the salts of some of the metals should have the exact amount of these ingredients which is contained in the average adult dose stated on the label.
Explanation of Rule 8: Objectionable Names
“Coined” Names.--Many of the abuses connected with proprietary medicines arise from “coined” proprietary trade names. Such names will not be recognized by the Council unless in particular instances the Council shall deem their use to be in the interest of public welfare.
In every such exception the burden of proof, both for establishing and for continuing the exception, lies with those who market the product.
Proprietary (“Trade”) Names When Permitted.--In consideration of the benefits which may come from the discovery of a therapeutic agent, the Council concedes to the person or firm which, by right of discovery, controls such a product the right to name it. The Council will offer no opposition to an arbitrary name for such a new product, provided it is not misleading, therapeutically suggestive, or otherwise subversive of scientific pharmacy and therapeutics.
If the discovery that a previously known substance has therapeutic value is deemed of sufficient importance, the Council may recognize a name for such a substance if the name is applied by the person who makes the discovery; or, with the consent of the discoverer or in the absence of any protest on his part, the Council may recognize a name applied by the firm which first makes such a product available to physicians.
In the interest of rational drug therapy, the Council recommends that trade names be coined so as to indicate the potent element or constituent.
Scientific Names.--When the proprietary or trade name for an article is considered insufficiently descriptive of its chemical composition or pharmaceutical character, the Council may require as a condition for the acceptance of such articles that a descriptive scientific name satisfactory to the Council appear on the labels, circulars and advertisements for such an article. For all definite chemical substances it is required that the scientific name be given prominence on the labels, in circulars and advertisements.
Proprietary Names for Unoriginal Articles.--Proprietary names will not be recognized for articles which are included in the U. S.
Pharmacopeia or National Formulary or for unessential modifications of such articles. Neither will proprietary names be recognized for substances or mixtures which are described in medical or pharmaceutical publications. In the marketing of unoriginal articles, the legitimate interests of the producer are fully served by identifying such products by appending the name or initials of the manufacturer or agent, or by the use of a general brand mark. No objection will be made by the Council to the use of such brand marks, provided that in no case shall such mark be used as a designation for an individual article.
For any product which, by reason of the absence or lapse of patent rights or for other reasons, is open to manufacture by more than one firm, the Council reserves the right to select a common name and to provide standards of identity, purity and strength, and then will accept such article only if it is marketed under the title adopted as the N. N. R. name or the name under which such article was introduced (to which may be appended the firm’s identifying mark).
N. N. R. to U. S. P.--When an article which has been accepted for New and Nonofficial Remedies is admitted to the U. S. Pharmacopeia or National Formulary, it will be omitted from New and Nonofficial Remedies one year after such standardization if the name of such article is used in these standards either as the main title for the product or as a synonym.
If the name under which the article is described in New and Nonofficial Remedies is not used in these books of standards, the proprietary preparation will be retained provided the official name is given prominence on the labels and in the circulars and advertisements of such article. When the Council adopts a common name for an article that has been admitted under another name, it will be continued under the older name only on condition that the Council name be given prominence on the label and in the circulars and advertisements for such article.
Pharmaceutical Preparations and Mixtures.--These, with rare exceptions, are not original in composition and there is seldom any reason why they should be endowed with arbitrary names. On the contrary, it is important that the prescriber should be reminded constantly of their potent ingredients.
Therapeutically Suggestive Names.--Articles bearing therapeutically suggestive names will not be accepted for New and Nonofficial Remedies, first, because they are likely to lead physicians into prescribing names instead of remedies, and second, because they tend to encourage unwarranted self-medication by the laity. Even if the name is at first apparently meaningless to the public, its meaning will soon be understood because patients soon learn the technical names applied to their diseases and symptoms.
The prohibition against therapeutically suggestive names is not applied to serums, vaccines and antitoxins, because the accepted nomenclature of the specific organisms used in their preparation makes this unavoidable and because self-medication with them is improbable.
Explanation of Rule 9: Patents, Trademarks, Copyrights, Etc.
Protection.--This information is important as a means of determining the legal status of medicinal articles and as an aid to their ready recognition in current publications.
Explanation of Rule 10: Unscientific and Useless Articles
Unscientific Compounds.--The use of articles which are unessential modifications of official or established nonproprietary articles is unscientific and serves no useful purpose. The Council will not accept products which are scientifically unsound and which, therefore, must be considered useless or inimical to the best interest of the medical profession and the public. This class includes compounds or mixtures containing an excessive number of active ingredients; those compounds or mixtures the components of which are of no probable assistance to one another, and those articles which are of no therapeutic value.
Unessential Modifications of Official Substances.--The subterfuge of obtaining proprietary rights over an official or established nonproprietary product, by introducing unessential modifications, also tends to confusion and abuses, and such articles will not be admitted by the Council.
Essential and important modifications, however, will receive recognition. (The Council interprets the term “established nonproprietary product” as applying to a preparation of any formula which has been published through any recognized or reasonably accessible channel of publication, prior to its appropriation or modification by a manufacturer.) Duplicates of biologic products accepted under the name of the manufacturers will not be accepted under the names of the distributors.
THE COUNCIL ON PHARMACY AND CHEMISTRY, PRESENT AND FUTURE[A]
W. A. Puckner, Phar.D.
Secretary, Council on Pharmacy and Chemistry
[A] Read before the Chicago Medical Society, March 26, 1919.
The World War marked an epoch in the existence of the Council on Pharmacy and Chemistry, as it did in all human endeavors. The information and experience which had been accumulated by the Council during its thirteen years’ existence was drawn on by our government, directly or indirectly, and it also received consideration in England, France,[1] Belgium, Holland,[2] Italy,[3] Sweden and elsewhere. In the world wide readjustment that has begun, the efforts of the Council, past and present, will influence the plans of those who engage in the manufacture or sale of medicines, and, undoubtedly, will be the incentive to the establishment of similar bodies in other countries.
[1] “New and Nonofficial Remedies” in France, Foreign News, J. A. M. A. =71=:1331 (Oct. 19) 1918; =70=:1783 (June 8) 1918.
[2] Nederl. Tjdschr. v. Geneesk. Oct. 5, 1918, p. 1201.
[3] An Italian View of the Proprietary Evil, Foreign News, J. A. M. A. =71=:840 (Sept. 7) 1918; The Council on Pharmacy and Chemistry and the Patriotic Medical League in Italy, ibid. =71=:918 (Sept. 14) 1918.
As secretary of the Council almost from the time of its organization in 1905,[4] and knowing the work of its members and its collaborators, I am firmly convinced that this body has deserved the endorsement and support given it by the American medical profession. I welcome this opportunity to present an outline of the Council’s past activities and to speak of some of the problems of the future, because I feel assured that a knowledge of its endeavor to improve drug therapy will increase the profession’s confidence in the Council and add to the number of its supporters.
[4] Although the Council on Pharmacy and Chemistry was established in 1905, it is likely that only a small percentage of physicians know just what the Council is, or have any conception as to its personnel and its ability to judge the available evidence for proprietary medicaments. The personnel has changed from time to time since 1905.
At present its membership is: C. L. Alsberg, A.M., M.D., chief of the Bureau of Chemistry, U. S. Department of Agriculture, Washington, D. C.; R. A. Hatcher, Ph.G., M.D., professor of pharmacology, Cornell University Medical College, New York City; A. W. Hewlett, M.D., professor of medicine, Leland Stanford Junior University Medical School, San Francisco; John Howland, M.D., professor of pediatrics, Johns Hopkins University Department of Medicine, Baltimore; Reid Hunt, M.D., professor of pharmacology, Harvard University Medical School, Boston; Henry Kraemer, Ph.D., professor of pharmacognosy, University of Michigan College of Pharmacy, Ann Arbor, Mich.; W. T.
Longcope, A.B., M.D., Bard Professor of the Practice of Medicine, College of Physicians and Surgeons of Columbia University, New York City; G. W. McCoy, M.D., director of the Hygienic Laboratory, United States Public Health Service, Washington, D. C.; Lafayette B. Mendel, Ph.D., Sc.D., professor of physiologic chemistry, Sheffield Scientific School, Yale University, New Haven, Conn.; F. G. Novy, M.D., Sc.D., professor of bacteriology, University of Michigan, Ann Arbor, Mich.;
W. W. Palmer, B.S., M.D., associate professor of medicine, College of Physicians and Surgeons of Columbia University, New York City; L. G.
Rowntree, M.D., professor of medicine, University of Minnesota Medical School, Minneapolis; Torald Sollmann, M.D., professor of pharmacology and materia medica, Medical Department, Western Reserve University, Cleveland; Julius Stieglitz, Ph.D., Sc.D., Chem.D., vice chairman of the Council, professor of chemistry, University of Chicago, Chicago;
G. H. Simmons, M.D., LL.D., chairman of the Council, editor of The Journal of the American Medical Association, Chicago, and W. A.
Puckner, Phar.D., secretary of the Council, director of the Chemical Laboratory of the American Medical Association, Chicago.
THE COUNCIL’S ACTIVITIES
Organized primarily for the purpose of putting a stop to false declarations with regard to the composition of proprietary medicines, the Council’s activities have broadened until its work may be characterized as “a propaganda for the rational use of drugs.” The following are some of its activities:
- New and Nonofficial Remedies.--This is an annual volume, issued
by the Council. It describes both proprietary and nonofficial, nonproprietary drugs which are deemed worthy of consideration by the medical profession. To be admitted to this book, a preparation must comply with certain definite rules which stipulate, in effect, that its composition be declared, that no untrue or grossly exaggerated claims be made for it, and that it shall give promise of having therapeutic value.
With the exception of a few which are still under consideration, the Council has considered all proprietaries whose owners or accredited agents have requested that an examination of the products be made, and it has admitted to the book those which were found eligible. In addition, the Council has examined all of the more important or widely exploited proprietaries, even when no examination was requested, and it has admitted those of this group which were found eligible.
Further, the Council has admitted to the book certain nonofficial, nonproprietary articles which seemed to give promise of therapeutic usefulness, and it has established standards for the control of their identity and purity, and listed those brands which complied with these standards.
As most proprietary medicines are of a more or less experimental nature, they are accepted for inclusion in New and Nonofficial Remedies only for a limited time--usually a period of three years. At the expiration of the period of acceptance, each preparation is reexamined and retained only if the claims made for it and the present day knowledge of its value permit this action.
Since manufacturers give information only in regard to their own products, New and Nonofficial Remedies groups together articles of a similar character, and includes in each case a general discussion of the group for the purpose of comparison, not only with each other, but also with the established or pharmacopeial drugs which members of the group are intended to supplant.
In brief, New and Nonofficial Remedies is a book in which are described preparations that have been accepted by the Council. The description includes facts that the physician should have. It is a book that should be in the hands of every physician who prescribes medicines, and who wishes to know the facts regarding the newest remedies. It is the only book in which he can find information relative to proprietary medicines that are worthy of his patronage.
It will protect the physician who makes use of it against the wiles of the promoters of products not worthy of his patronage. It would certainly be of use to the physician when the detail man calls on him, for if he were being importuned to prescribe or use samples of something which he had not heretofore used and which he was unable to find in N. N. R., he might ask the detail man why.
In the nature of things few physicians are sufficiently expert in chemistry and allied sciences to be able unerringly to discriminate between the true and the false as regards many preparations that he is asked to prescribe.
- The Reports of the Council on Pharmacy and Chemistry.--A
medicament may be inadmissible to New and Nonofficial Remedies for various reasons; it may be worthless or irrational, its composition may be secret or indefinite, or it may be exploited under exaggerated or unwarranted claims or in a way otherwise detrimental to the public health and scientific medicine. Of these various reasons which make an article unacceptable, the manufacturer obviously may remove all except the first, viz., worthlessness or irrationality.
Consequently, a preparation which has been presented for admission is not definitely rejected until after its proprietor has been informed of the objections to his product and has failed to bring the preparation in conformity with the Council’s rules. When a preparation is found definitely inadmissible to New and Nonofficial Remedies, that is, when the proprietor cannot or will not make it acceptable, the Council prepares a report for publication.
These reports are sent for publication to The Journal of the American Medical Association, and later published in the annual “Reports of the Council on Pharmacy and Chemistry.” The more important of these are also published in the book, “The Propaganda for Reform in Proprietary Medicines.”
- Useful Drugs.--Since the domination of proprietary medicines,
which was retarding medical advance and threatening therapeutic chaos, had been made possible only by the insufficient and inefficient instruction given in medical schools in subjects having to do with drugs, the Council appointed a Committee on Medical Teaching to secure the cooperation of teachers in materia medica, pharmacology and related branches. This committee has endeavored to effect an improvement in these courses of instruction.
One of the results of this work was the selection of a list of drugs to serve as a basis of materia medica instruction and thus insure that medical students shall be better informed with regard to the therapeutic worth of a few well established drugs, rather than, as in the past, leaving school with a smattering of knowledge about many drugs. The outcome of these efforts is the publication of “Useful Drugs,” a concise but thorough and up-to-date discussion of the actions, uses and dosage of the more important drugs.
The list of drugs presented in this book is now the basis of instruction in many schools; and many state examining boards are confining their materia medica questions to the drugs in the list.
- Epitome of the U. S. P. and N. F.--To encourage the use of
official drugs and to make available an estimate of their therapeutic value, a committee of the Council prepared an abstract of the U. S.
Pharmacopeia and the National Formulary. This booklet, the “Epitome of the U. S. Pharmacopeia and National Formulary,” presents those portions of these books which are of interest to physicians, and in addition, gives a concise statement of the therapeutic usefulness of the drugs and preparations described in them.
- Patent Law Reform.--Some of the worst abuses connected with the
exploitation of proprietary medicines have been made possible by our patent and trademark laws and the method of their interpretation and enforcement. The Council, therefore, appointed a committee to study these laws and the various propositions advanced for their improvement.
This committee has published, from time to time, reports on various phases of our patent and trademark laws and recently summarized these reports in an address[5] sent to the commissioner of patents and the interested congressional committees. It is hoped that by means of these reports physicians will be enabled to give intelligent support to a revision of the patent and trademark laws when legislation is proposed.
[5] Need for Patent Law Revision, A. M. A. Council on Pharmacy and Chemistry Reports, 1917, p. 130.
- Therapeutic Research.--Through its Committee on Therapeutic
Research, and with the aid of funds provided by the Board of Trustees of the American Medical Association, the Council has encouraged the investigations of questions which might lead to a better understanding of the action of drugs. These investigations are brought together in the annual reports of the Committee on Therapeutic Research, and are an important addition to our knowledge of drug action.
In the past, the Council has in particular encouraged the investigation of the action and therapeutic value of widely used drugs regarding which our knowledge is still unsatisfactory. These investigations have included a study of the action of strychnin in cardiac disease, a comparison of the action of absorption and excretion of iodid preparations, a study of the pharmacology of the opium alkaloids, etc.
Appreciating that the available knowledge of proprietary drugs is one sided in that it comes from investigations made by interested pharmaceutical concerns or from investigations made at the instigation of these firms, the Council is planning a comprehensive study of many of the synthetic drugs that have gained some vogue during recent years.
THE FUTURE
Medical research, and efficient instruction in therapeutics and related subjects, spell a diminishing influence of commercial medicine over rational therapeutics. The fact that the present shortage of German synthetics has not handicapped seriously the practice of medicine should be a lesson to American physicians for many years to come.
On the other hand, it must be remembered that the publicity given to the reports of the Council and to other contributions toward rational therapeutics by The Journal of the American Medical Association, the journals of the state organizations, and a few personally owned publications, is as nothing when compared with the persistent and wide publicity given to the propaganda of the proprietary houses. While a report setting forth the objections to a proprietary is published but once, the firm’s laudatory pronouncement goes forth again and again until the Council’s report is completely overwhelmed and forgotten.
Manufacturers of proprietaries not only keep in close touch with the practicing physician by means of house organs, special “literature,” or by traveling representatives, but many of the firms, through the meritorious lines of pills, tablets, tinctures, etc., which they put out, also obtain and hold the good will and confidence of a large proportion of the medical profession.
Furthermore, some of these firms may gain the confidence of the medical profession through these high grade pharmaceuticals, and certain of their proprietaries may be of distinct therapeutic value but may fail to be acceptable for New and Nonofficial Remedies, because they do not conform to the reasonable rules of the Council.
These firms do not find it profitable to force the sale of their regular nonproprietary pharmaceuticals by unwarranted claims or objectionable methods, yet they may consider it good business to market certain proprietary products by means of claims which are extravagant and without warrant, and which will lead to indiscriminate use by the profession and the public.
In a word, where there is one dollar spent on behalf of rational medicine, thousands are spent for the purpose of increasing the sale of preparations which directly or indirectly are a detriment to the public health, to medicine, and to the pocketbook.
That the day of the secret nostrum of the pseudo-chemical company is not yet past is well illustrated by the recent introduction of an asserted arsphenamin preparation called “Syphilodol.” The A. M. A.
Chemical Laboratory proved one form of this asserted French discovery to be essentially a pill of mercurous iodid. Another form of Syphilodol (for intravenous administration) had all the characteristics of water, and appeared devoid of any potent ingredient. Though the advertising sent out by the promoters in regard to its composition was suspiciously evasive, the Illinois Medical Journal published an advertisement of “Syphilodol,” which, possibly by a coincidence, appeared above an appeal to “Our Readers” to use wares advertised in that journal.
While such rank deceptions as “Syphilodol” are not common, there are more subtle deceptions that are even more dangerous. Types of widely exploited remedies of today comprise so-called ethical specialties composed of well known and established drugs (with “jokers” hidden away somewhere) or preparations which have a plausibly fascinating pseudo-scientific background of radiant energy, colloidal chemistry, nonspecific protein reaction, or something of the sort. The latter class of preparations in particular appeal to physicians who are striving hard to keep pace with modern science. Exposure of their fallacies requires most careful consideration on the part of the Council.
Progress toward a rational and scientific drug therapy must continue, and, therefore, it is important that the Council on Pharmacy and Chemistry should continue to make the investigation of proprietary medicines its chief work. Investigation of a proprietary medicine, however, and a report of such investigation are of value in direct ratio only to the number of physicians who read the report, endorse it and act in accordance with its conclusions.
In order that you may determine to what extent those preparations which are admitted to New and Nonofficial Remedies deserve your interest and confidence, it will be worth while briefly to outline the rules which govern the Council in the admission of articles to New and Nonofficial Remedies.
RULES GOVERNING THE ACCEPTANCE OF ARTICLES FOR N. N. R.
Composition.--Rules 1 and 2, and in a measure 5, 7, and 9, deal with the composition of articles. Rule 1 requires that the quantitative composition of an article be furnished the Council for publication.
Rule 2 requires that the manufacturer furnish methods whereby the composition of products that are definite chemicals or the potent constituents of mixtures may be determined. The Council does not require that the process of manufacture of an article be declared unless this becomes necessary in order to judge its composition. Rule 5 requires that statements with regard to the origin and source of an article shall be truthful. Rule 7 requires that for the guidance of the dispenser, the amounts of poisonous ingredients of a preparation be placed on the label. Rule 9 requires that if patent rights are claimed for a product, the Council be informed on this point.
That it is not only the right but also the duty of the physician to know the composition of what he prescribes for his patients is so generally admitted that few have attempted to market preparations of avowedly secret composition. When the Council first began its work, it was common to see chemical formulas or statements of composition published which a chemist or a pharmacist was able to pronounce at a glance as impossible.[6] It was not unusual to find that the promoter published “a formula” for his preparation, rather than “the formula.”[7] Today, however, a more prudent, if not more honest, course is pursued.
This gives a “formula” which is correct so far as it goes, but which fails to divulge the actual composition of a preparation.
When it is considered that many physicians are not any too conversant with the chemistry and pharmacy of drugs, it is not surprising that some administered the proprietary “Venarsen,” regarding the composition of which they had only the vague statement that it was “... a comparatively nontoxic organic arsenic compound, 0.6 gm. representing 247 mg. (3-3/4 grains) of metallic arsenic in chemical combination ...” in the belief that a preparation similar to that first introduced as salvarsan was being used. That “Venarsen” contained its arsenic as sodium cacodylate--a notoriously inactive state of combination--does not justify the intravenous administration of a drug of unknown composition.
[6] Puckner, W. A.: The Abuse of Chemical Formulas, Reports A. M. A.
Chemical Laboratory =3=:7, 1910.
[7] The Formula for Glyco-Thymoline, J. A. M. A. =52=:147 (Jan. 9) 1909.
While for the present it probably is not feasible to require, on the part of those who manufacture medicinal preparations, such professional training as is required of those who prescribe and those who dispense them, it certainly is not too much to require, as does Rule 2, that a manufacturer shall be able to demonstrate that his preparation has the composition claimed for it. Nor is it sufficient for him to know that the ingredients claimed as constituents were used in the manufacture.
The fallacy of his method of reasoning was furnished by the physician who reported that he had personally added the required amount of mercuric iodid for a batch of “Mercol” which, nevertheless, was devoid of mercury.[8] Acceptance of this rule by manufacturers will permit physicians to have a more accurate knowledge of the composition of preparations such as “Taka-Diastase”[9] and “Iodeol”.[10]
[8] Hunt, Reid, and Seidell, Atherton: Howell’s Mercol, J. A. M. A. =52=:225 (Jan. 16) 1909. Howell’s Mercol Again: Another Analysis Fails to Reveal the Presence of Mercury, J. A. M. A. =52=:1595 (May 15) 1909.
[9] Taka-Diastase and Liquid Taka-Diastase: Report of the Council on Pharmacy and Chemistry, J. A. M. A. =59=:50 (July 6) 1912.
[10] Iodeol and Iodagol: Report of the Council on Pharmacy and Chemistry, J. A. M. A. =69=:1725 (Nov. 17) 1917.
A requirement similar to that of Rule 5 is contained in the Federal Food and Drugs Act and so no objection has been made to this rule which requires a truthful statement of the origin and source of articles. An illustration for the need of the rule was furnished by the one time popular “Vin Mariani”[11] which, though very French in its makeup, was found to be largely of the “made in the United States” variety of tipple.
[11] Vin Mariani: Official Report of Council on Pharmacy and Chemistry--With Comments, J. A. M. A. =47=:1751 (Nov. 24) 1906.
The issuance of a patent for a medicinal product does not prove that such a product presents a discovery or that its owner is entitled to a temporary monopoly, yet it is only fair to physicians and to other manufacturers that notice of such patent claims be given. Hence, the Council publishes in New and Nonofficial Remedies the information bearing on this point.
Lay Advertising.--Rules 3 and 4 provide against the recognition of articles that are advertised to the public directly or indirectly, exempting from this requirement preparations which the Council believes are safe to be so advertised.
It has been held with some justice that certain shotgun proprietaries are purchased by the public with as much circumspection as they are ordered by those physicians who are addicted to the prescribing of them; but even the exploiters of these mixtures have not denied that the use of medicines by the public on its own initiative is surrounded with many objections. Hence the practice of self medication should not be encouraged by prescribing or using those preparations advertised for public use.
The only objection to the rule has come from a firm which markets a brand of liquid petrolatum, the Standard Oil Company of Indiana. The Council has considered the question of exempting simple laxatives from the restrictions of Rules 3 and 4 as it has exempted antiseptics and nonmedicinal foods. The conclusion was, however, that the excessive use of a simple laxative like a liquid petrolatum, when prompted by newspaper exploitation, is likely to be detrimental to health by overuse as well as by misuse.
The indirect advertisement to the public, which Rule 4 provides against, has been the means of inducing the extensive lay use of “Antikamnia,” “Bromidia” and “Fellows’ Syrup.” Naturally Rule 4 has been bitterly opposed by most proprietary firms. Arguing that many physicians dispense their own drugs, pharmaceutical firms have insisted that every medicinal preparation should bear on its label, not only the dose of the preparation, but also a statement of the diseases in which the article is indicated.
Whether manufacturers anticipated the profession’s resentment toward the claim that physicians determine the treatment and perhaps the diagnosis by means of the statements on labels, or because the Shirley amendment to the Food and Drugs Act makes the proprietor responsible for therapeutic claims on the label of a medicine, it is a fact that fewer preparations than formerly need to be refused on account of infringement on this rule.
In fact, some thoroughly objectionable proprietaries make a show of being “ethical” by omitting all therapeutic discussion from the labels of their preparations.
Therapeutic Claims.--Rule 6 makes ineligible for New and Nonofficial Remedies any articles regarding which the manufacturer or his agents make unwarranted, exaggerated or misleading statements as to the therapeutic value. Recognizing the long established custom of therapeutic exaggeration, it has been most difficult to determine the degree of conservatism which might with fairness be required of a manufacturer. In view of the common acceptance of individual impressions as dependable evidence, it is often almost embarrassing to declare as incompetent the statement of some well meaning and all-too-kind-hearted doctor.
However, as the pitfalls of haphazard clinical trials become better known and the physician’s mistrust of glowing accounts of marvelous cures more outspoken, the manufacturers’ claims will be more moderate.
Nomenclature.--Were it possible to enact and enforce a law which would oblige manufacturers to sell their medicinal products under properly descriptive names and which would make it illegal for a physician to prescribe it unless he understood the meaning of such properly descriptive titles, then the Council might safely disband. In that case, physicians would discontinue the use of most proprietary preparations in favor of established drugs, and successful newcomers might each year be counted on the fingers of one hand. Such a rational nomenclature is not to be thought of, at least in our generation.
Rule 8 requires that the name of an article shall not be misleading, that it shall not be therapeutically suggestive, and that established drugs shall not be disguised by fanciful titles. It recognizes the right of discoverers of new drugs to name their discoveries, and interposes no objection to arbitrary names for such products so long as such names are not misleading or do not suggest the therapeutic uses of the products. As the rule provides against the recognition of coined names for established nonproprietary drugs, so it requires that mixtures of drugs shall bear names descriptive of their composition.
It would be a long step forward if physicians would recognize more fully the objections to the many proprietaries which have, as their only point of originality, a non-descriptive name for an old drug or a mixture of well known drugs. It is an encouraging sign that the Federal Trade Commission, when issuing licenses for the manufacture of synthetic drugs introduced under German patents, stipulated that all manufacturers authorized to make a given drug shall use the same name for it.
Irrational Articles.--Rule 10 provides against the recognition of an article which, because of its composition, is useless or inimical to the best interests of the public and medical profession. This rule excludes medicaments which (1) are unessential modifications of established articles, or (2) are of no therapeutic value or (3) are irrational. With regard to the recognition of mixtures or compounds containing two or more active ingredients, the Council requires that the manufacturer establish the rationality of its combination. The rule has prevented the recognition of many unnecessary so-called ethical specialties.
Though a mass of testimonials was often to be had for them, these contained no evidence that the mixture was superior to its potent ingredient, or that its therapeutic effect had been determined.
That there is a healthy tendency to use single drugs for their definite action and to discard combinations (be they shotgun proprietaries or “mixed” vaccines) is perhaps best illustrated by the fact that at the last revision of the U. S. Pharmacopeia a considerable number of complex antiquities were omitted from that book.
Feeling confident that this meets with the endorsement of the profession, the Council is examining more critically the evidence for the value of pharmaceutical mixtures.--(From The Journal A. M. A., May 10, 1919.)
“ACCEPTED BY THE COUNCIL ON PHARMACY AND CHEMISTRY”
Under the caption given above, the Journal of the Missouri State Medical Association, in its July issue, speaks editorially as follows:
The Council on Pharmacy and Chemistry of the American Medical Association is a department of our national organization that has not received the plaudits and encomiums of a wildly joyous medical profession nor the grateful praises of the enthusiastic manufacturer of pharmaceuticals. The Council seems indeed to be the unloved child of the entire family of subsidiary bodies of the association.
Perhaps the reason for this may be found in the character of its duties, for the Council must expose fraud, sometimes in high places, and protect the physician from being duped by avaricious persons and by persons who are themselves sometimes the victims of their own credulity. It thus happens that the sale of some proprietary article previously held in high esteem by the practitioner proves valueless, perhaps even fraudulent.
The practitioner, however, may have credited much of his success in treating certain conditions to that preparation and the maker has had success in accumulating dollars from its sale and both parties emit a loud and vicious roar against the Council, because they both lose money. Nobody wants to be “protected” against making money--make it honestly, if possible, but make it--but this black sheep among the Councils of the American Medical Association insists on their making their money honestly!
Despite many obstacles thrown into its path, the Council on Pharmacy and Chemistry has serenely pursued its allotted tasks, corrected its mistakes, improved its methods, and today stands as the only medium to which the honest physician may turn for information--not misinformation--regarding proprietary articles. During the war the Council and the chemical laboratory were in close cooperation with the Surgeon-General’s Office, testing and investigating every article offered to the government for the treatment of sick soldiers.
The variety and the number of fakish and fraudulent stuff offered to the Surgeon-General was a pitiable exhibit of the mental gymnastics of some people. Just now the Council and the laboratory have a new and important field before them, i. e., to protect the physicians against worthless and useless serums, vaccines and synthetics. It will be the Council’s unpleasant duty to expose the fraudulent and useless among these articles and stamp truth on those found worthy.
We seem to have wandered from the topic in our caption, but not so in reality, because the burden of our thought is to lend our influence to the spread of the motto of the Advertising Clubs of the World, namely, “Truth in Advertising.” It is our purpose to stimulate a larger degree of enthusiasm for the work of the Council on Pharmacy and Chemistry and the Chemical Laboratory, a more generous flow of inquiries concerning articles unfamiliar to the physician, and particularly to urge that the words “Accepted by the Council on Pharmacy and Chemistry of the American Medical Association” be printed on the label and on all advertising circulars of proprietary articles that have been admitted to New and Nonofficial Remedies.
Then, when pamphlets and circulars are received by physicians they will read the statements of manufacturers with sympathetic understanding and with full confidence in the verity of the declarations. The importance of creating just that sort of receptivity in the mind of the prospective buyer is so well known to the astute publicity expert that it is needless for us to dwell on its advantages.
Every proprietary article advertised in our journal, in The Journal of the American Medical Association, and in the other state association journals, as well as in several well-edited privately owned journals, does in effect say to the reader that the articles so advertised are accepted by the Council because only proprietary articles so accepted are accepted by us.
The fact is further acknowledged when these firms are permitted to exhibit their goods at our annual sessions for again the rule is enforced that only proprietary articles which have been approved by the Council may be placed on display.
Why not complete the circle of ideas--it would not be a “vicious circle”--by printing on labels, in advertisements and circulars, the words: “Accepted by the Council on Pharmacy and Chemistry”?--(From The Journal A. M. A., Aug. 2, 1919.)
HELPING THE COUNCIL
If they were built that way, the members of the Council on Pharmacy and Chemistry of the American Medical Association might become discouraged at the apparent indifference of many members of the medical profession to their efforts. There are many physicians who, while figuratively patting the Council on the back, actually do nothing to aid its efforts. On the other hand, there are men in the profession who give the Council active support instead of merely passive appreciation.
The letter that follows was written by such a man to a pharmaceutical concern:
I am receiving circular advertising from you concerning ---- ----
solution, and I am writing to suggest that until these products
have been approved by the Council on Pharmacy and Chemistry of
the American Medical Association, you are wasting your postage
on the practice. Aside from the fact that these products do not
appeal to me personally, I feel that I am not in a position to
judge the value of such products and I depend entirely on the large
clinical opportunities of the Council on Pharmacy and Chemistry of
the American Medical Association in addition to their laboratory
facilities, in such matters as these.
I may, therefore, with all
due respect, suggest that ... it will pay you to eliminate my name
from your mailing list.
The members of the Council on Pharmacy and Chemistry are working week in and week out without remuneration. Few appreciate how much these scientific men are doing for rational therapeutics; fewer still realize how much has been accomplished through their efforts, or how much more could be accomplished if every physician who at least believes in the work of the Council would give it his full support.--(Editorial from The Journal A. M. A., Nov. 6, 1920.)
DELAYS IN PASSING ON PRODUCTS
Report of the Council on Pharmacy and Chemistry
The Council has adopted the following report and authorized its publication.
W. A. Puckner, Secretary.
The Council frequently receives inquiries--some of them accompanied by expressions of impatience--concerning articles, reports on which appear to be delayed. It therefore seems advisable to make a statement of some of the factors which enter into this problem.
The Council fully realizes the importance of giving prompt information to the profession with regard to proprietary medicines under consideration. It therefore acts as soon as sufficient information is available to justify a definite judgment, and publishes its conclusions as soon as possible. When adequate information is available at the outset, there is no delay in the publication of the Council’s conclusions.
Unfortunately, but very naturally, there are many cases in which the information available at the time the product is submitted is not sufficient to justify the Council in coming to definite conclusions for or against the preparation. In some cases the manufacturer possesses the required information, but to obtain it from him takes time; in other cases the manufacturer does not possess the information--perhaps he did not realize the inadequacy of his evidence until the subject was brought to his attention by the Council.
Such cases might be dealt with in either one of two ways: The Council might at once reject the article because the claims for it are not supported by adequate evidence; or, the Council might suspend judgment and give the manufacturer an opportunity to supply the information.
The first method--immediate rejection--would obviously be felt by manufacturers as a hardship. To afford the fullest possible opportunity for the presentation of the case, the Council follows the second method; that is, it suspends judgment and withholds publication of a report until reasonable time has been afforded for furnishing the required information, provided the manufacturer or agent appears to be making honest and diligent efforts to supply it. The collection and compilation of such information is sometimes a lengthy process, especially when the products are of foreign manufacture.
Although it would be easier for the Council to render an immediate decision than to assist manufacturers to supply the data necessary for the formation of an authoritative judgment, the Council cannot yield to importunities for hasty action. It must rely on the medical profession to bear in mind that the character of a product under consideration by the Council has not yet been determined. The Council holds that, during this stage, a product is suitable, at most, for experimental use.--(From Reports of Council on Pharmacy and Chemistry, 1915, p. 119.)
COOPERATION OF THE PHARMACEUTICAL HOUSES
Report of the Council on Pharmacy and Chemistry
In reply to the suggestion made last year by President Bevan that there should be closer cooperation between the large pharmaceutical houses and the Council on Pharmacy and Chemistry, the Council submitted to the Board of Trustees of the American Medical Association the statement which appears below:
“COOPERATION OF THE PHARMACEUTICAL HOUSES: At the opening meeting
of the House of Delegates last year, President Arthur Dean Bevan
suggested the desirability of greater cooperation between the large
pharmaceutical houses and the Council on Pharmacy and Chemistry. The
need of such cooperation has been recognized by the Council from the
first. In no one direction has the Council made greater effort than
in its endeavor to secure the fullest cooperation of the various
pharmaceutical houses.
The difficulty has been, and always must
be, the fundamental antagonism between objectives that are largely
commercial on the one hand and purely scientific on the other.
Nevertheless, the Council has always believed--and has acted on the
belief--that there is a possible middle ground wherein the interests
of therapeutics would not be injured but would go hand in hand with a
commercial development based on enlightened self-interest.
“The profits to be made by a pharmaceutical house from the sale of a
staple drug--a pharmacopeial, National Formulary, or nonproprietary
preparation--which enters into free competition with other drugs
of the same kind, are moderate; the profits to be made from the
sale of a proprietary medicine on which the manufacturer holds a
monopoly are usually large--sometimes enormous.
There are, broadly,
two kinds of proprietary preparations advertised to physicians:
One represents laborious research ending in the production of
a new medicinal chemical; this product can be patented and the
manufacturer can obtain a seventeen-year monopoly on its manufacture
and sale. The other represents no research but comprises simple
mixtures--frequently of the “shotgun” variety--of well known
pharmaceuticals, or biologic products sold under trade names. As
these do not represent anything new or original the manufacturer is
unable to obtain a patent, but by means of the trade name he can and
does obtain a perpetual monopoly.
This, from a business standpoint,
is more valuable than the limited monopoly granted by a patent. It is
not surprising that proprietary remedies of the latter type flourish
so long as physicians unthinkingly accept and prescribe them solely
on the manufacturer’s valuation.
“The Council has practically the undivided support of
manufacturers of medicinal chemicals; that is, of proprietaries
of the first mentioned type. But pharmaceutical firms which
have found it profitable to promote proprietaries of the second
type--“specialties,” unscientific or ordinary mixtures of
pharmaceuticals or biologic products sold under trade names--have not
supported the Council.
“When the Council was organized, it was hoped and believed that all
the large pharmaceutical houses would find it possible and desirable,
if not actually more profitable, to shape their business methods so
as to make their proprietary and other articles conform to those
conservative standards on which the Council bases its rules, and thus
render such articles acceptable for New and Nonofficial Remedies.
It soon developed, however, that the methods of the pseudochemical
companies, whose sales propaganda in the interest of unscientific
nostrums with its attending damage to scientific medicine had led to
the establishment of the Council, had found their lodgment in most
of the pharmaceutical houses.
It was a genuine disappointment to the
Council to find that some of the large and old-established firms
were not only unwilling to cooperate with the Council, but in many
instances exhibited a definite antagonism to the Council’s work.
“The object--and duty--of the officers of pharmaceutical houses is
primarily to pay dividends to their stockholders. Through skilful
advertising or the persuasiveness of “detail men,” they are able
to induce physicians to prescribe their controlled products, on
which there are large profits, even though such products have not
only not been accepted by the Council, but in many instances, have
been disapproved. Is it any wonder that concerns which put out such
products are indifferent or openly antagonistic to the work of the
Council? The matter is largely one of business policy.
When the
medical profession as a unit will support the Council in its work,
then such firms will find it good business policy to accede to Dr.
Bevan’s suggestion--but not before.”
Evidently the problem resolves itself into this: The Council, constituted of scientific men, working without remuneration in the interest of scientific medicine and the medical profession, expects--and rightfully--the cooperation and support of the members of that profession. What is needed, therefore, is the active, sympathetic cooperation of physicians; the cooperation of pharmaceutical houses will follow as a matter of course. (J. A. M. A. =74=:1235 [May 1] 1920.)
The following is the recommendation of the Reference Committee to which the Report of the Board of Trustees was referred: “A perusal of the Trustees’ Report, ‘Cooperation of the Pharmaceutical Houses’, is well worth the time of every member of the profession, and your committee would emphasize the statement of the Trustees: ‘The Council, constituted of scientific men, working without remuneration in the interest of scientific medicine and the medical profession expects--and rightfully--the cooperation and support of the members of that profession.
What is needed, therefore, is the active sympathetic cooperation of physicians; the cooperation of pharmaceutical houses will follow as a matter of course.’
“Your committee would go still further and move that a vote of thanks of the House be extended to those scientific men who have devoted so much valuable time to the welfare of the Association.”
(J. A. M. A., =74=:1322 [May 8] 1920; from Reports of Council on Pharmacy and Chemistry, 1920, p. 56).
W. A. Puckner, Secretary.
BUDWELL’S EMULSION OF COD-LIVER OIL, NOS. 1 AND 2
Report of the Council on Pharmacy and Chemistry
The Budwell Pharmacal Company, Lynchburg, Virginia, which markets these preparations, claims that “No. 1” contains cod liver oil, “Iodide of Arsenic,” “Iodide of Calcium,” and “Iodide of Manganese.” “No. 2” is said to contain in addition to the ingredients of No. 1, creosote carbonate and guaiacol.
It is known that arsenous iodid is decomposed by contact with water. It is recognized that creosote carbonate is unstable and prone to liberate creosote. Iodide of manganese not being official, the supply on the market is not controlled in any way: Tests of purity are not prescribed by the Pharmacopeia, the National Formulary, New and Nonofficial Remedies or other books of standards. Therefore doubt must be expressed as to the accuracy of the formulas as given. The Council cannot accept such statements of composition without further evidence.
“No. 1” is commended for use in
“Chronic Rheumatism, Glandular Swellings, later forms of Syphilis,
convalescence from Scarlet Fever, La Grippe and Malaria, Chronic
Malarial Infection, Marasmus, Joint or other suppuration of
standing, diseases of skin, chorea, anaemia, neurasthenia,
obstinate neuralgia, scrofulous affections in general, and diarrhea
or dysentery (subacute or chronic) in childhood.”
“No. 2” is said to be
“Prepared especially for the treatment of Chronic Throat, Nasal,
Bronchial and Pulmonary Diseases.”
In the advertising circular statements regarding the various ingredients of Budwell’s Emulsion are quoted from obsolete text books. These statements, for the most part, do not represent modern opinions on the subject. For instance, the circular praises the action of guaiacol as eliminated directly by the lungs, thus exerting a beneficial local effect and causing bacilli to diminish in numbers or to disappear. All of this is directly contradicted in authoritative modern publications on pharmacology, which hold that the excretion of guaiacol by the lungs is infinitesimal and its action on bacilli is nil. The Council held the preparations in conflict with its rules as follows:
- Many of the therapeutic claims are exaggerations.
- The method of exploitation amounts to an indirect invitation to the
public to use these preparations as “consumption cures.”
- The preparations are unscientific, they constitute a reprehensible
invitation to uncritical prescribing and their use is inimical to the best interests of the profession and the public. It is difficult to imagine in what conditions such a combination would be indicated. These preparations are a remnant of the days of polypharmacy. Their use is not in keeping with present medical thought and practice.--(From The Journal A. M. A., Feb. 20, 1915.)
RHEUMALGINE
Report of the Council on Pharmacy and Chemistry
Rheumalgine (Eli Lilly & Co., Indianapolis) is put up both in tablet form and as a liquid. Each tablet, or teaspoonful of the liquid, is said to contain:
“Strontium salicylate from Natural Oil 5 gr.
Hexamethylenamin 2 gr.
Colchicine 1/200 gr.”
The advertising matter contains several statements regarding the individual ingredients to which objection must be made.
It is claimed (quoting from Hare) that strontium salicylate
“... is not so disagreeable to the taste as the corresponding
sodium salts, and more important still, it is far less apt to
disorder the stomach.”
“Taste” is a difficult subject to dispute; but in the experience of the referee, patients object more to the strontium than to the sodium salt.
No evidence is submitted to prove that the strontium salt is less apt to disorder the stomach. In observations made under the direction of the referee, the nauseant and emetic doses are about the same as, or even less than, those of sodium salicylate.
Under hexamethylenamin, the recommendations are not confined to its recognized use as a urinary antiseptic; it is also said to be “unexcelled” as a “germicide,” and to prevent the formation of urate and phosphate deposits. These statements are contrary to facts.
“Rheumalgine ... may be used in all cases where the salicylates
are indicated. It is superior to preparations containing sodium
salicylate, in that it does not cause nausea or disturb the
digestion.”
Both the preceding statements are misleading. The necessity of giving 1/200 grain of colchicin for each 5 grains of salicylate would certainly interfere with the use of adequate doses of the latter. The colchicin would produce digestive disturbance quite apart from the salicylate.
The mixture is described as:
“... ANTIRHEUMATIC, ANTIPYRETIC, URINARY ANTISEPTIC, AND URIC
ACID ELIMINANT. Useful in Acute Articular and Chronic Rheumatism,
Muscular Pains, Lumbago, Sciatica, Migraine of the Rheumatic, Gout,
and in Nervous Irritability of the Gouty or Lithemic.”
The facts are: Salicylates are useful in some of these conditions, colchicin occasionally in a few, hexamethylenamin in none.
The combination is conducive to uncritical prescribing. For instance, salicylates are effective in acute articular rheumatism; hexamethylenamin and colchicin are useless; salicylates are of very little use in chronic rheumatism, sciatica and nervous irritability, while hexamethylenamin and colchicin are useless in these conditions; colchicin is sometimes effective in gout, salicylates perhaps also; hexamethylenamin is not.
Attention should also be called to the high dosage of colchicin, namely, 1/100 to 1/50 of a grain of the alkaloid, every three or four hours, the dose then to be “slightly reduced,” but continued for several days; or in chronic cases, 1/100 to 1/30 grain per day, continued indefinitely. This dosage appears high, if a really active preparation is used.
Finally, the name “Rheumalgine” encourages thoughtless and unscientific prescribing. If a mixture is used at all, the prescriber should be constantly reminded of its composition.
It is therefore recommended that Rheumalgine be held in conflict with Rules 6 (unwarranted therapeutic claims), 8 (nondescriptive name) and 10 (unscientific composition).--(From The Journal A. M. A., June 26, 1915.)
GRAY’S GLYCERINE TONIC
Report of the Council on Pharmacy and Chemistry
The Council adopted the following report and authorized its publication.
W. A. Puckner, Secretary.
Gray’s Glycerine Tonic Comp. (Purdue Frederick Company, New York) is a mixture said to be made according to a prescription of the late Dr.
John P. Gray, superintendent of the state hospital, Utica, New York. As to the composition, the following statement is furnished by the company:
“This preparation is a combination of Glycerine, Sherry Wine,
Gentian, Taraxacum and Phosphoric Acid with carminatives.”
The label declares the presence of 11 per cent. alcohol, and the dose is given at from two teaspoonfuls to a tablespoonful. A study of the ingredients will show that, aside from the alcohol, the mixture contains but one really active drug, gentian. Essentially, then, “Gray’s Glycerine Tonic” is a mixture which, in addition to the narcotic effect of the alcohol, depends on a bitter, gentian, for whatever therapeutic action it may possess.
The bitters, of which gentian is a type, were once credited with many therapeutic virtues which time has shown they do not possess.
Pharmacologic research has demonstrated that their utility consists in stimulating the appetite through their action on the taste buds. On this account they were believed also to increase the secretion of the gastric juice by a psychic impression. More recently, however, even this has been questioned--by Carlson, for instance.
These facts are fully understood, presumably, by all physicians. Yet, according to the advertising circular, this “tonic,” which, for all practical purposes, is merely a simple bitter, is good for thirty-two diseases ranging from amenorrhea to whooping cough!
The conditions in which Gray’s Glycerine Tonic is asserted to be especially efficient are described on the label of the bottle and the outside wrapper, in popular terms, more or less typical of “patent medicine” exploitation, such as “catarrhal conditions,” and “stomach derangements.” Similar statements are contained in the leaflet accompanying the trade package. For instance:
“It is, therefore, an effective, reliable tonic in nervous
exhaustion, general debility, impoverished conditions of the blood
and nervous system, Bright’s disease, diseases of the liver,
disorders of the urinary organs, etc.”
“It is an unexcelled restorative in that very common class of cases
in which there is no positive organic disease, but the patient
complains that he ‘does not feel well’ or ‘is out of sorts.’”
Here are some of the claims made in other advertising matter:
“All stages of bronchitis ... are rapidly improved by the use
of Gray’s Glycerine Tonic Comp. This remedy has a direct tonic
influence upon the circulation of the respiratory mucous membrane;
it relieves congestion and restores tone to weakened blood vessels.”
“... improves the appetite, gives valuable aid to the digestive and
absorptive processes, and reinforces cellular nutrition in ways
that insure a notable gain in vitality and strength.”
+-----------------------------------------------------------------+
| In Gastro-Intestinal Catarrh |
| |
| --and other afflictions of the stomach and bowels characterized |
| by muscular weakness and glandular insufficiency--there is no |
| remedy more prompt and effective in its action than |
| |
| Gray's Glycerine Tonic Comp. |
| |
| Under its systematic administration the appetite is restored, |
| the alimentary processes greatly improved, the nutrition |
| promoted and every vital function throughout the body given a |
| new and substantial impetus.
As the digestive and assimilative |
| functions are restored to their normal efficiency, a notable |
| increase in the restorative and recuperative powers of the body |
| naturally follow. |
| |
| THE PURDUE FREDERICK CO. |
| 135 Christopher Street, New York City |
+-----------------------------------------------------------------+
Mention ILLINOIS MEDICAL JOURNAL when writing to advertisers.
[Illustration: This appeared in a journal owned and controlled by the second largest state medical association of the country.]
Even granting that gentian may improve the appetite, how absurd it is to claim that this mixture “relieves congestion,” “restores tone to weakened blood vessels,” “gives aid to the absorptive processes,” “reinforces cellular nutrition,” or increases vitality!
Neither the composition of Gray’s Glycerine Tonic nor the clinical evidence warrants the belief that it has any therapeutic value other than that due to the psychic effect of the bitter drug gentian.
Physicians who have prescribed it have done so because of the advertising. This nostrum has been kept so constantly before the eyes of medical men that they think of Gray’s Glycerine Tonic when they cannot remember the official drugs that may be indicated in the case.
The moral is that liberal advertising will sell anything.
It is recommended that Gray’s Glycerine Tonic Comp. be declared not eligible for inclusion in New and Nonofficial Remedies on account of conflict with Rules 1, 6, 8 and 10.
[Editorial Note.--An old practice in hospitals--happily now practically obsolete--was to have certain stock mixtures prepared in bulk. Among these there was usually a so-called tonic mixture, used in a more or less haphazard manner when nothing in particular seemed indicated. Such a stock mixture was used in the State Hospital for the Insane at Utica, N. Y., during the many years that Dr. John P. Gray was superintendent (from the early fifties to the early eighties), although it is very doubtful whether he originated the mixture. After the death of Dr.
Gray--so the story runs--one of his sons, with a partner, formed the firm of Purdue Frederick Company, and began the exploitation of the elder Dr. Gray’s name, in connection, presumably, with this stock preparation. As indicated in the Council’s report, Gray’s Glycerine Tonic Comp.--and what an absurd name!--is simply a mixture of ordinary drugs, requiring no skill whatever in compounding. If there is a physician living who cannot write a prescription offhand as good as this formula, that physician should either go back to a medical school or change his vocation.
There is, and can be, no excuse for prescribing such a ready-made mixture, for every cross-roads drugstore has the ingredients and any pharmacist worthy of the name could compound it.
Among the scores of nostrums that disgrace the medical profession of this country, none is more typical of all that is inimical to scientific medicine, to the medical profession and above all to the public--for, after all is said, it is the public that ultimately is humbugged.]--(From The Journal A. M. A., July 10, 1915.)
TONGALINE AND PONCA COMPOUND
Report of the Council on Pharmacy and Chemistry
The Council, having considered “Tongaline,” “Tongaline Tablets,” “Tongaline and Lithia Tablets,” “Tongaline and Quinine Tablets” and “Ponca Compound Tablets,” found these preparations ineligible for New and Nonofficial Remedies and authorized publication of the following report.
W. A. Puckner, Secretary.
TONGALINE
Tongaline (Mellier Drug Co., St. Louis) is a fancy name given to what is essentially a sodium salicylate mixture. The air of mystery created by the name permits the manufacturers to make claims for the product which would be ludicrous if the medical profession was fully conversant with the very ordinary character of the preparation.
Tongaline receives its name from tonga, an inert, long-discarded mixture of various barks and herbs said to be gathered and prepared by Fiji Islanders. Its constituents evidently tend to vary with the collector. The history of the introduction of this indefinite combination of simples is thus given in The Journal, May 10, 1913.
“A supply of the crude drug was carried to England by a man who had
lived for a short time in the Fiji Islands and it was placed in the
hands of a retail house in London. This occurred about 1879. In
1880, two English physicians of repute published laudatory articles
on the therapeutic value of tonga in neuralgia and rheumatism. This
created a demand for the drug which extended to the United States.”
Time showed that tonga was inert therapeutically, and authorities on pharmacology now no longer notice it. As the Council previously reported,[12] the indefinite character of the mixture should, alone, be sufficient to exclude it from practical therapeutics. During the temporary popularity of tonga, the proprietary mixture Tongaline was put on the market for physicians’ use by the Mellier Drug Company, St. Louis. In this, tonga was named as the active ingredient. The commercial interests thus involved have faithfully nourished and kept alive the “tonga” myth.
[12] Reports of the Council on Pharm. and Chem., 1912, p. 40.
In a recent advertising booklet, “The Therapeutic Properties of the Ingredients of Tongaline,” the virtues of tonga, blue cohosh, colchicum, jaborandi and salicylic acid are discussed. The label of a recently purchased bottle reads:
“Tongaline contains Tonga, Cimicifuga Racemosa, Salicylate of
Sodium (the salicylic acid being made from pure natural oil)
Colchicum and Pilocarpin.”
It will be noticed that Tongaline is “made from the pure, natural oil.”
In fact, the statement is repeated in red ink, in large letters running across the face of the label, thus emphasizing the alleged importance of this assertion. In this connection it is only necessary to recall that it has been proved clinically, chemically and physiologically that there is absolutely no difference between the salicylic acid made from the natural oil and the synthetic.
The formula was thus commented on in the article previously quoted from The Journal:
“Tongaline ... is essentially a preparation of sodium salicylate,...
The Mellier Drug Company realized the impossibility of creating
any marked demand for a nostrum unless it had some real drugs
in it--hence the presence of the salicylates. What the actual
composition of Tongaline is, no one but the manufacturers know. At
one time the following was given as the formula:
Fluid Tonga 30 grains
Extract of Cimicifuga Racemosa 20 grains
Sodium Salicylate 10 grains
Pilocarpin Salicylate 1/100 grain
Colchin Salicylate 1/500 grain
“These amounts refer to the quantity of drugs in each fluidram of the
preparation. Whether the nostrum still has this composition we do
not know, but assuming that it has, it is quite evident that sodium
salicylate is the essential and active ingredient.”
The therapeutic indications given on the label of the bottle are:
“Rheumatism, Neuralgia, Grippe, Gout, Nervous Headache, Sciatica,
Lumbago, Malaria, Tonsillitis, Heavy Colds, Excess of Uric Acid,
and wherever the use of the Salicylates is indicated.”
In a recent booklet this semisecret salicylate mixture is recommended, not only in conditions in which salicylates are indicated, but also combined with aconite for rheumatic fever, with benzoate of soda in the treatment of “grippe,” with potassium bromid in nervous headaches, with gelsemium, glycerin and whisky for “heavy colds,” with ammonium chlorid, stramonium and cimicifuga in “rheumatic dysmenorrhea,” and even with mercury biniodid as a treatment of syphilitic eruptions!
“When administered with good judgment, Tongaline exerts a
stimulating effect upon every organ of elimination; cleansing
the complex sewerage system and putting it into working order.
When this is done, the sluggish blood current begins to flow more
freely; the lymphatic and glandular systems to give up and carry
off the toxic products, so long retained ...”
TONGALINE TABLETS
Then because of a “desire to put Tongaline in a more compact and convenient form,” the same concern puts on the market Tongaline Tablets. Whether Tongaline Tablets are of the same composition, the doctor who prescribes them is not advised. In this form we have Tongaline and Lithia Tablets, and Tongaline and Quinin Tablets.
Presumably those who are attracted by the word “lithia” are sufficiently uncritical to be content with the statement that:
“The addition of Lithia to Tongaline presents a most useful
combination which does not rely upon its action on the kidneys
alone as is the case with Lithia salts or Lithia waters as
administered ...”
And the foregoing quotation, be it remembered, is for the information of the medical profession! Tongaline and Lithia Tablets, we are informed, are:
“... particularly indicated for certain diseases which are caused
by deposits of urates in the joints and kidneys, and can be used
with much benefit for many people who indulge in generous or
intemperate habits of living.”
Tongaline and Quinine Tablets are also exploited without statement of composition. The promoters are probably justified in feeling that physicians who prescribe quinin in combination with “Tongaline” care little about the dosage.
It is unnecessary to discuss the silly claims made for Tongaline and its combinations, although it is worth while to point out that the prescribing of such nostrums by physicians is an imposition, if not a fraud, on the public.
PONCA COMPOUND
Ponca Compound, also made by the Mellier Drug Company, St. Louis, is a “female weakness remedy” in tablet form. The name suggests that “ponca” is a medicinal substance, and, in fact, at one time, “Ext. Ponca” was named as an ingredient. The nature of “Ext. Ponca” was apparently never explained. It is now replaced in the “formula” by “senecin,” and the only information concerning the composition at present given is:
“Ponca Compound Tablets Contain Extract of Mitchella Repens,
Senecin, Helonin, Caulophyllin and Viburnin.”
This “formula” is practically meaningless, not only because the amount of each ingredient is not stated, but also because “senecin,” “helonin,” “caulophyllin” and “viburnin” are in themselves variable mixtures of unknown composition.[13]
[13] See Report of the Council on Pharmacy and Chemistry on “Resinoids and Concentrations,” J. A. M. A., Nov. 13, 1909, p. 1655.
Presumably, “senecin,” “helonin,” “caulophyllin” and “viburnin” are extractives of some kind prepared, respectively, from senecio aureus (life root), helonias dioica (false unicorn), calophyllum thalictroides (blue cohosh) and viburnum prunifolium or opulus (black haw or cramp bark). These are, one and all, practically inert drugs. There is no reason to believe that any or all of them can have any beneficial influence in the many and varied conditions for which Ponca Compound is advertised.
The following are excerpts from the advertising matter:
“Ponca Compound is a remedy of a very beneficial character for
Functional, Uterine and Ovarian troubles, which will respond to
internal treatment, especially when digital examination or surgical
interference is undesirable.”
“Ponca Compound is also valuable during gestation and after
parturition.”
“Uterine Alterative for Leucorrhoea, Dysmenorrhoea, Amenorrhoea,
Metritis, Endometritis, Menorrhagia, Metrorrhagia, Irregular
Menstruation, Subinvolution, Painful Pregnancy.”
It is recommended that Tongaline and Ponca Compound and all their preparations be held in conflict with Rule 1, in view of their semisecret and indefinite composition; with Rule 6, for the grossly exaggerated therapeutic claims made for them; with Rule 8, because of their misleading names, and with Rule 10, in view of their unscientific character as irrational combinations. It is also recommended that this report be published.--(From The Journal A. M. A., July 17, 1915.)
ALFATONE
Report of the Council on Pharmacy and Chemistry
The Council has found Alfatone ineligible for New and Nonofficial Remedies and has authorized publication of the following report.
W. A. Puckner, Secretary.
Alfalfa is good cattle feed but only nostrum exploiters have suggested its use as a medicine for human beings. While it may seem a waste of time to discuss the medicinal value of alfalfa its recent exploitation by the Norwich Pharmacal Company, Norwich, N. Y., as “a reconstructive tonic and nutrient” in the form of a mixture called “Alfatone,” calls for comment. According to the label on the preparation:
“Each fluidounce represents:
Alcohol 15 per cent.
Medicago sativa (Alfalfa) 120 grains
Taraxacum 2-1/2 grains
Gentian 1 grain
Berberine Hydrochloride 1/40 grain
Glycerin and Aromatics.”
“Dose.--One to three fluidrams (4 to 12 c.c.) 4 times daily.”
Each maximum dose, therefore, should represent 45 grains of alfalfa, 1 grain of taraxacum (dandelion), 3/8 grain of gentian, 1/100 grain of berberin hydrochlorid, and 27 minims of alcohol. Since the bitter drugs are present in such small amounts that the preparation is almost devoid of bitterness, and as the medicinal value of alfalfa is practically nil, it is evident that whatever action Alfatone may have is due to the stimulant effects of the alcohol.
Some of the claims made for Alfatone are:
“A reconstructive nutritive tonic indicated in general debility,
neurasthenia, convalescence, etc.”
“... a Galactagogue of merit as well.”
“... improves the appetite, aids the processes of digestion and
assimilation, facilitates elimination and effects gradual but
decided gains in strength, vitality and weight.”
It is suggested that:
“... in case of idiosyncrasy the addition of Tr. Nux Vomica 5 to 10
minims to the dose, unless contraindicated, will secure excellent
results.”
The Norwich Pharmacal Company naively remarks:
“The dearth of medical literature on Alfalfa has lead us to present
below a few of the findings of the Bureau of Plant Industry of the
Department of Agriculture ... as well as those from several state
experiment stations ...”
Here are the “findings”:
“... Digestible nutrients in 100 pounds of Alfalfa,... Protein,
11.0 pounds; Carbohydrates, 39.6 pounds; Ether Extract, 1.2 pounds.”
“... The high value of Alfalfa is due to the amount of protein that
it contains; to the large percentage of protein that is digestible
and the palatability of Alfalfa.”
“... Table showing pounds of elements removed from the soil by one
ton of crop.
Alfalfa Wheat
Potash 49.79 12.52
Phosphoric Acid 8.27 9.08
Lime 43.51 2.95
Nitrogen 44.01 22.30”
“... The abundance of muscle and bone producing material in Alfalfa
makes this crop especially good.”
Thus estimates of the value of a farm crop and cattle fodder are made to do service as testimonials to its therapeutic merit for human beings! Has the “patent medicine” promoter ever dared to insult the intelligence of his patrons by a cruder absurdity? Yet it is not to the nontechnical and unscientific public, but to a profession presumably scientifically trained in pharmacology and therapeutics that this concern presumes to offer its fodder tincture on the basis of testimony to the agricultural value of the fodder plant.
Alfatone is a worthless alcoholic cordial. The audacity of the attempt to promote its sale by a discourse on the merits of a well-known fodder plant is the sole reason for devoting any attention to it. It is recommended that Alfatone be held ineligible for New and Nonofficial Remedies, and that this report be published.
[Editorial Note.--What a comment on American medicine that a concern can even contemplate the possibility of making a commercial success of the sale of such a silly nostrum as Alfatone! And yet, when one remembers that a proprietary in which oats constitutes one ingredient (“Pas-Avena”) for years has been advertised to physicians and presumably prescribed by them, it is not altogether inexplicable that business men should get the impression that the medical profession is “easy” enough to “fall for” anything in the line of proprietary mixtures.
Perhaps we may look forward to being offered proprietaries based on other cheap and well-known fodder plants. Tincture of Timothy Hay, Blue Grass Tonic, Cornhusk Wine! Why not? The enterprising companies that may put them out can easily publish tables to show the digestible nutrients in each and indubitable testimony can be furnished to prove the excellence of any of them as stock feed.
If a pitchforkful of timothy hay makes a good fattening ration for a growing steer why should not a teaspoonful of tincture of timothy hay make a “reconstructive tonic and nutrient” dose for a man? If an arm load of thistles (carduus) makes a luscious food for equus asinus why should not a pinch of thistle in alcohol and water be a good “tonic”? Great are the possibilities! They are limited only by the gullibility of the medical profession and the public.
Certain it is that some proprietary manufacturers are firmly convinced that no combination can be too preposterous to be worth trying on the medical profession.]--(From The Journal A. M. A., Aug. 7, 1915.)
ARTICLES REFUSED RECOGNITION
Report of the Council on Pharmacy and Chemistry
Below appear abstracts of the Council’s actions on articles refused recognition which were not deemed of sufficient importance to require lengthy reports.
Uricsol
Uricsol is marketed by the Uricsol Chemical Company, formerly of Los Angeles, now of Boston. Regarding its composition only vague statements are made. In an advertising pamphlet it is promised that the formula will be sent to physicians on request. Such a request from a physician elicited the following statement:
“URICSOL is a non-irritating, alkaline solution, containing Lithium
Citrate, Acid Citric and Potassium Nitrate, together with a saline
laxative in the form of Glycero Sodium Phosphate, with Vegetable
Tonics added.”
The Association Laboratory has made an examination of Uricsol to determine its composition and reports as follows:
LABORATORY REPORT
A trade package purchased in March, 1915, from a wholesale drug house was labeled:
“Uricsol Rheumatic Remedy, Uric Acid Solvent, Kidney and Liver
Stimulant, Manufactured by the Uricsol Chemical Co., Los Angeles,
Cal.”
This package was wrapped in a circular entitled “The Great California Remedy--Uricsol.” The preparation is a viscid, slightly turbid light brown liquid, with a faintly aromatic odor and a salty, bitter taste. The diluted solution is acid in reaction toward litmus and phenolphthalein and alkaline toward methyl orange.
Qualitative tests showed a presence of phosphate, citrate, nitrate, sodium, glycerin, and a small amount of lithium in aqueous solution.
Besides these a small amount of some organic, nonalkaloidal substance was found, which from its bitter taste suggested gentian. From the qualitative tests it appeared that the phosphate was the predominating ingredient and accordingly a phosphate determination was made. The results, calculated to sodium phosphate, U. S. P., indicated the presence of 64.20 gm. per 100 c.c., held in solution by citric acid and sodium nitrate.
Uricsol evidently is a solution containing a large amount of sodium phosphate with small amounts of lithium, nitrate, citric acid and glycerin, with probably some vegetable extract.
In general Uricsol is similar to the once widely exploited proprietary “Melachol,” which has been frequently imitated. A preparation essentially identical is in the United States Pharmacopeia, under the title “Compound Solution of Sodium Phosphate.”
The Uricsol Company calls its preparation
“... the latest word in the treatment of Rheumatism and that allied
group of ailments which is caused by an excess of Uric Acid.”
Hay fever, bronchial asthma and neuritis are conditions in which it is recommended. The claim is made that
“Uricsol quickly controls Vasomotor Rhinitis and eliminates such
conditions from the system.” “In fact, it will correct FAULTY
METABOLISM.”
To a few practitioners of an older generation the pharmacologic basis of a remedy for rheumatism was sufficiently defined by saying that it increased the solubility of uric acid or affected it in some way. This theory is obsolete; there is not, and never was, any reliable evidence on which to base the theory that rheumatism is in any way caused by uric acid. The exploitation of Uricsol as a “uric acid solvent” is merely another illustration of the way in which nostrum manufacturers play on disproved theories. Of course the claim that sodium phosphate has any particular power to control vasomotor rhinitis, hay fever, asthma, and to correct faulty metabolism is foolish.
To summarize: Uricsol is a mixture of well-known drugs, marketed with false claims as to therapeutic action, with misleading and meaningless statements as to composition and under a name which invites uncritical prescribing. Uricsol is held ineligible to inclusion in New and Nonofficial Remedies.
Jubol
The following ridiculous statements are addressed, not to the laity, but to the medical profession:
DO YOU SUFFER FROM Constipation--Hemorrhoids--Enteritis--Mucous
discharge--Pituita--Acidity of the stomach--Vertigo--Sick
Headache--Disturbed Sleep--Insomnia--Sallow Complexion--Coated
Tongue--Offensive breath--Fatigue and depression--Boils--Pimples?
“ONE of these symptoms alone shows that there is defective or
insufficient function of the intestines, even if the stools are
regular.
“Excrements remain too long in the intestine and set up
fermentation. The harmful poisons and Ptomains which they produce
are re-absorbed by the blood and poison the whole system.
“The Intestines must be cleared and re-educated with JUBOL.
“Jubolise your Intestines.”
Jubol tablets are sold in the United States by Geo. J. Wallau, Inc., New York, and are said to be prepared by J. L. Chatelain, Paris, France. The following incomplete and nonquantitative “formula” is furnished:
“... compounded chiefly [!] of Agar-Agar, Biliary Extracts and pure
Extracts from all the intestinal Glands.”
It is asserted that
“The tablets are coated with a protective covering in order that
they may act on the intestine only.”
The tablets contained in a regular-size trade package, obtained direct from the agent, readily separated into two halves and disintegrated within a few minutes when agitated with water. It is thus evident that, under ordinary conditions, the intestinal ferments in Jubol (if they are present, as claimed) would be destroyed during their passage through the stomach. In direct tests, however, practically no tryptic activity was demonstrated.
The composition of Jubol is not declared; grossly unwarranted and incorrect claims are made for its therapeutic actions; the name does not indicate the alleged ingredients and so much of the composition as is declared indicates an unscientific mixture. The Council decided that Jubol should be held ineligible for New and Nonofficial Remedies, and that this report should be published.
Urodonal
Urodonal is said to be “produced in the laboratory of J. L. Chatelain,” Paris, France. It is marketed in this country by Geo. J. Wallau, Inc., New York.
The preparation is claimed to be a chemical compound, and the advertising matter furnishes a “formula,” which consists of the formulas of lysidin, sidonal and hexamethylenamin, connected by plus signs:
{H₂C Az } CO₂H--C--OH AzH Az
{H₂C C--CH₃} + { H₂C CHOH } {H₂C CH₂} {H₂C CH₂ CH₂}
{ AzH } {OHHC CH₂ } {H₂C CH₂} + {Az.CH₂ Az.CH₂ Az}
{ CHO } { AzH } { CH₃ }
That the substance is a chemical compound is highly improbable, and no evidence has been submitted to substantiate the claim. On the contrary, in the following statement the phrase “based on” is a virtual admission that the preparation is merely a mixture:
“Urodonal ... is a granular effervescent preparation based on
methylglyoxalidine [Lysidine], quinate of diethylene-diamine
[Sidonal] and hexamethylene-tetramine [Formin, urotropine].”
Mystery is added by the mention of undefined “special products” in the following:
“The fact of combining these two salts [lysidin and sidonal] in
Urodonal, in strictly determined proportions and in the presence of
special products, gives this preparation very considerable power in
dissolving uric acid.”
These contradictory statements of composition conflict with Rule 1.
Urodonal is marketed in typical “patent medicine” style: the name “Urodonal” is blown in the bottle and the label contains a list of “Indications,” including rheumatism, gout and gravel (Rule 4). That this form of marketing has introduced it to the public is suggested by the following in an advertising circular:
“... Urodonal is now popular--even classic--throughout the world,
where thousands of doctors and millions of patients agree in
asserting that ‘Urodonal is to rheumatism what quinine is to
fever.’”
There are also other indications that the mixture is to be exploited to the laity. For instance, the U. S. distributor sends out a portrait of Sarah Bernhardt bearing the legend:
“I am positive that URODONAL preserves youth’s freshness with
clearness and strength to brain and heart. I have taken it for two
years with the greatest benefit. Sarah Bernhardt.”
A circular advises this mixture
“For all who suffer from Arthritis, Rheumatism, Arterio-Sclerosis,
Renal and Bilious Lithiasis, Headache, Gout, Gravel, Lumbago,
Sciatic Pains, Neuralgia and all uric acid troubles.”
“In fact, Urodonal is five times more active than piperazine, and
thirty-seven times more active than lithia. We are, therefore,
entitled to say that no other eliminator of uric acid can be
compared with it.”
“Being 37 times more active than lithia, it clears the heart
valves of any sandy substances which may clog them, and checks the
atheromatous degeneration of the blood vessels.”
These extracts indicate sufficiently the extravagant tone of the advertising (Rule 6): None of the ingredients are notably active in dissolving uric acid when administered by mouth. None produce any marked increase of uric acid elimination. No intelligent physician would use a uric acid solvent for “bilious lithiasis”; and their usefulness in the other conditions is open to doubt, to put it mildly.
Although the preparation is a simple mixture, the name does not indicate the components, but inclines to therapeutic suggestion (Rule 8).
Nothing is to be gained by combining several drugs which are useless, severally, for the purpose intended, as in the present case (Rule 10).
Urodonal is marketed under inconsistent statements of composition and with exaggerated therapeutic claims; the name is nondescriptive and the mixture is unscientific. The Council decided that the preparation should be declared ineligible for conflict with Rules 1, 4, 6, 8 and 10 and that this report should be published.--(From The Journal A. M. A., Aug. 14, 1915.)
FORMAMINT
Report of the Council on Pharmacy and Chemistry
The following report has been authorized for publication.
W. A. Puckner, Secretary.
Formamint is a proprietary medicine manufactured by the A. Wulfing Company (New York, London and Berlin), which is affiliated with the Bauer Chemical Company.
It has been widely advertised in Europe for several years, and is now on the American market;[14] it is advertised in this country both in newspapers and medical journals.
[14] The Journal A. M. A., Feb. 24, 1912, p. 572.
Following is a brief review of the more important alleged investigations that have been reported from time to time in various European journals.
In “The Therapeutical Value of Foramint in Septic Affections of the Oro-Pharynx,” De Santi[15] quotes Rosenberg,[16] who reports the successful use of Formamint in cases of streptococcus infections, tonsillitis and acute symptoms of chronic sore throat. According to Seifert,[17] Formamint is a chemical combination of formaldehyd and milk sugar. When the tablets are dissolved in the saliva, 0.01 per cent. of formaldehyd in its “status nascendi” is liberated and exercises a strong disinfectant action.
Seifert states that the preparation is markedly palatable, since it contains a little citric acid to render the taste cool and refreshing. In some experiments with streptococci, pneumococci, typhoid and diphtheria bacilli, Seifert found that a solution of one tablet in 10 c.c. of water destroyed these germs in from five to ten minutes.
A solution of the same strength was also added to culture tubes of broth, agar, and gelatin, with the result that no growth occurred in them, while distinct and characteristic development of the bacteria took place in control tubes. He does not state, however, how much Formamint solution was added to the mediums.
[15] De Santi: Medical Magazine =16=:141, 1907.
[16] Rosenberg: Lancet, London =2=:1871, 1905.
[17] Seifert: Pharmakol. u. therap. Rundschau, 1904, No. 14; quoted by De Santi (Note 2).
Daus[18] reports successful treatment of tonsillitis, mumps and middle ear diseases. In these cases no other gargles or mouth washes were used. He states that no indication of irritant or other injurious action made its appearance even after large doses. In the same article, F. Levy reports experiments as follows: Agar plates were prepared with a culture of streptococcus from a severe case of quinsy. One half of the plate was rubbed with saliva containing Formamint in solution. (The strength of the solution used is not given.) In twenty-four hours streaks of growth had appeared on one portion of the plates while the part on which the Formamint saliva had been rubbed remained sterile.
Daus also found that agar and broth cultures of streptococcus shaken with Formamint saliva remained sterile.
[18] Daus: Med. Klin. =2=:4110, 1906.
Rheinboldt,[19] investigating the effects of Formamint and of ordinary formaldehyd on animals, concludes that formaldehyd is toxic in action while Formamint is not.
[19] Rheinboldt: Deutsch. med. Wchnschr. =32=:587, 1906.
[Illustration: How the exploiters of Formamint capitalize the medical profession. Miniature reproductions of typical Formamint advertisements appearing in the newspapers.]
Rosenberg[20] corroborates this statement. He also found that agar plates of Bacillus prodigiosus were killed by Formamint solutions in about four hours. He fails, however, to give the strength of his Formamint solutions.
[20] Rosenberg: Therap. d. Gegen. =7=:55, 1905.
Wingrave[21] suggests the use of Formamint for infants! He recommends that a tablet be crushed and wrapped in “butter cloth.” The ends of the cloth are to be tied with thread, the Formamint is to be moistened, and the packet is to be held in the mouth of the baby several times each day.
[21] Wingrave: Lancet, London =2=:1067, 1906.
Young[22] published the results of some experiments by himself and Delépine on the human throat. They dissolved a tablet in the mouth and made swab cultures with the following results:
Immediately after taking the tablet 0 colonies
10 minutes after taking the tablet 35 colonies
30 minutes after taking the tablet 150 colonies
[22] Young: Lancet, London =1=:975, 1908.
They found no staphylococci at any time. Other results of swabbing various parts of the throat before and after the use of Formamint, reported by these investigators, show enormous reductions in the count, claimed to be due to the action of Formamint. The count was made on agar at 37 C., but they fail to state the time elapsing between taking the Formamint and making the swab. Young also reports favorable clinical results in cases of scarlet fever, diphtheria, sore throat, and the like. It must be noted, however, that they state that the mouth and fauces must first be thoroughly cleansed by swabbing and douching before Formamint is used.
THE “CHEMICAL COMPOUND” CLAIM
The claims made in the advertising literature of Formamint are very extravagant. Many are highly improbable. These statements will be discussed later.
The statement is made that Formamint is a new chemical compound:
“Formamint is Pentamethanallactose, 5 CHOH + C₁₂H₂₂O₁₁. It is an
original combination of Formaldehyde with Lactose, a definite
chemical compound. The Formaldehyde molecule is locked up in it
until solution in the saliva takes place, when the Formaldehyde is
liberated in its nascent state and is therefore active without
being irritant.”
Furthermore the makers contend that this new chemical compound is entirely harmless. For example, Daus,[5] in an article on “The Disinfectant Action of Formic Aldehyde on Mucous Membranes,” declares:
“No indication of irritant or other injurious action made its
appearance even after large doses. The urine remained free from
albumin and sugar.”
Such statements as these are found in the advertising literature:
“Formamint tablets are absolutely harmless and innocuous, even to
little children.”
“When dissolved in the saliva, Formamint Tablets liberate slowly
Nascent Formaldehyde in a most active yet non-irritant form.”
They maintain that Formamint is not only absolutely harmless, but actually beneficial to the tissues. It may be used “to tone up and strengthen the tissues, prevent hoarseness, and allay irritation in singers, public speakers,” etc.
The claims urged as to its germicidal power are indeed glittering. This “new chemical compound” is claimed to liberate formaldehyd in some new and peculiar condition which, while it has a soothing and tonic effect on the cells of the human tissues, can at the same time quickly kill any form of bacterial life.
“Dissolving readily, it releases its germicidal, antiseptic
qualities, which impregnate the saliva and are carried naturally
and easily around the mouth and in the deepest crevices of the
throat--destroying the germs where they are causing the mischief.
Formamint prevents and destroys infectious germ life in a soothing
grateful way.”
“In the saliva it frees a germicide, fatal to germs but harmless
to the most delicate membranes. And flowing into every tiny corner
of the gums, tonsils and throat, into places where no gargle ever
reaches, it most effectively disinfects the throat.”
The claims as to the preventive and curative effects of the preparation cover a large portion of the category of human ailments and distresses.
The following quotations indicate some of its supposed properties:
“... it is therefore self-evident that Formamint should be
looked upon as a necessary part of the treatment of all forms of
tonsillitis.”
“The value of Formamint is equally great in diphtheric tonsillitis,
or as a prophylactic ...”
“The extraordinary success which I had with Formamint in a
school epidemic of scarlet fever during May and June, 1907, was
the determining factor which induced me to abandon the use of
inhalations, gargles, local applications in the treatment of
diseases of the throat, and to use Formamint exclusively for the
future.”
“There are naturally many similar conditions in which Formamint
may be used as a prophylactic, notably scarlet fever, mumps,
streptococcal and staphylococcal sore throats, ‘milk outbreaks’ of
sore throat, drain throats, hospital throats, and the like.”
“Formamint Tablets are indicated in Angina, Tonsillitis,
Pharyngitis, Stomatitis, Gingivitis, Glossitis, ulceration, spongy
or bleeding gums, Pyorrhea Alveolaris, ‘Smoker’s Sore Throat,’
Abscess or Boils, etc.”
“As a Prophylactic against Diphtheria, Scarlet Fever,
Influenza, Measles, Epidemic poliomyelitis, and other pathogenic
micro-organisms. To neutralize putrefaction products in and about
the teeth, correct fermentative processes, deodorize and purify the
breath, etc.”
“To tone up, and strengthen the tissues, prevent hoarseness
and allay irritation in singers, public speakers, neutralize the
effects of dust-infection or disinfect the saliva or sputum in
Influenza, Tuberculosis, etc.”
One man declares that along with specific constitutional treatment he “had the best results from the use of Formamint tablets” in a case of syphilitic ulceration of the tongue.
In short, Formamint is recommended for the treatment or prevention of almost everything, from a bad breath to such grave conditions as scarlet fever, diphtheria and tuberculosis, conditions in which a delay in proper treatment--for instance, in diphtheria, a failure to administer antitoxin--may result in the death of the patient.
A series of investigations was therefore undertaken in order to discover whether the extravagant claims regarding the germicidal power of Formamint could be verified.
Experimental Data
Two fifty-cent bottles of Wulfing’s Formamint were purchased in the open market and were kept well stoppered to prevent deterioration.
Qualitative tests showed the presence of formaldehyd and the amount was determined quantitatively by the hydrogen peroxid method as given by Sutton.[23] The results were respectively, 1.99 per cent. and 2.03 per cent. of formaldehyd.
[23] Sutton: Volumetric Analysis, Edition 10, p. 390.
[Illustration: Two Formamint advertisements reproduced in miniature typical of those appearing in a certain type of medical journals.]
Some determinations were made of the germicidal power of Formamint in vitro, that is, under controlled laboratory conditions. A twenty-four-hour plain agar culture of Staphylococcus aureus was washed off in 10 c.c. of sterile 0.85 per cent. sodium chlorid solution. A 1:100,000 dilution of this was made in each of three flasks containing 100 c.c. of sterile saliva. Flask 1 contained 1 per cent. of Formamint, Flask 2, 5 per cent.; Flask 3, containing no Formamint, was kept as a control. At intervals samples were removed and dilutions made and plated in duplicate on standard agar.
The plates were incubated twenty-four hours at 37 C., and plates containing less than 200 colonies were counted. The results are given in Table 1. After seven days there was no appreciable difference in the plates.
Another test was made by adding a 1 per cent. Formamint solution to plain agar plates inoculated with B. coli. A twenty-four-hour plain agar culture of B. coli was washed off in 10 c.c. of sterile 0.85 per cent. sodium chlorid solution. A 1:1,000,000 dilution was made of this and 1 c.c. added to each plate. Varying amounts of 1 per cent. solution of Formamint were added to each plate. They were incubated seventy-two hours at 37 C. After seven days’ incubation the count was the same. The results are given in Table 2.
Another experiment was made thus: One loopful of a twenty-four-hour plain agar culture of Streptococcus lacticus was mixed with a tube of North medium. One loopful from the inoculated tube was mixed with a second tube of North medium. Both tubes were poured into Petri dishes and allowed to cool. One half of each plate was well smeared with a 10 per cent. solution of Formamint in saliva. After twenty-four hours’ incubation at 37 C., only a few colonies appeared on the side to which the Formamint had been applied, while the other half was thickly covered with colonies.
TABLE 1.--SHOWING TIME IN WHICH CULTURES OF STAPHYLOCOCCUS AUREUS WERE
KILLED BY DIFFERENT AMOUNTS OF FORMAMINT
+=================+=============+
Amount of Formamint| Period of |Average Count| Count on Flask
in Saliva |Standing at 37 C.| When Plated |of Saliva Without
(Per Cent.) | (Hours) | | Formamint
-------------------+-----------------+-------------+-----------------
1 | 3 | 32 | 3200
1 | 6 | 0 | 7000
5 | 1 | Few | 5000
5 | 2 | 0 | 4100
5 | 3 | 0 | 3200*
5 | 6 | 0 | 7000*
-------------------+-----------------+-------------+-----------------
- The last two observations were made at the same time as on the 1 per
cent. solutions.
This work so far corroborates that reported in the literature quoted by the manufacturers. But the fact that a compound is a germicide when brought into intimate contact with bacteria in a solution or medium in a test tube or flask does not prove that it will be effective when used in the human throat.
THE ALLEGED GERMICIDAL ACTION
An attempt was made to discover whether or not the claims advanced by the manufacturers as to the perfect germicidal action of Formamint in all the nooks and crannies of the mouth and throat could be confirmed.
TABLE 2.--COUNT OF B. COLI CULTURES WITH DIFFERENT AMOUNTS OF FORMAMINT
No. c.c. of 1 per cent. Formamint 0 0.1 0.3 0.5 0.7 1.0 1.5 2.0 3.0
Count 160 33 39 26 15 12 2 0 0
----------------------------------------------------------------------
The first step in attacking this problem was to make comparative counts of the number of bacteria in the throat before and after the use of Formamint. The methods employed were as follows: The throat was gargled with 50 c.c. of sterile 0.85 per cent. sodium chlorid solution. In each case the same length of time, as far as possible, was used in the process. The liquid was collected in a sterile flask. The gargling in a series of experiments was begun not less than two hours after a meal.
After some preliminary work the following dilutions of the 50 c.c. of salt solution were found sufficient: 1:1,000, 1:10,000 and 1:100,000.
Plates were made in duplicate from each dilution and incubated seventy-two hours at 37 C. The counts were made on plates containing less than 200 colonies. Except where otherwise noted standard agar was used. The mediums were always prepared in the same way.
All the work was carried out under conditions as nearly natural as possible. The Formamint was taken according to the directions accompanying the trade package. Every opportunity was given the Formamint to penetrate all the crypts and recesses about the mouth and throat. The tablet was allowed to dissolve as slowly as possible, the time usually being five to six minutes, and saliva was thoroughly forced around the mouth before being swallowed. Plating was always done immediately after gargling so that no growth could occur in the salt solution. The results are given in Table 3.
The numbers are average counts from several plates and calculated to show the number of bacteria washed out by the 50 c.c. of salt solution.
TABLE 3.--SHOWING THAT FORMAMINT DOES NOT GREATLY DECREASE THE NUMBER
OF BACTERIA IN THE THROAT
+=========+=========+===========+
| | |No. Found |No.
Found
| Time |Amount of|in Throat |in Throat
Conditions of Test | Since |Formamint| Before | After
|Preceding| Used | Use of | Use of
| Test | |Formamint |Formamint
--------------------------+---------+---------+-----------+-----------
Normal | ... | 0 | 15,600,000| ...
Normal | 1 hour | 0 | 38,500,000| ...
Normal | 1 hour | 0 | 30,500,000| ...
Normal | ... | 0 | 12,500,000| ...
Normal | 1 hour | 0 | 14,500,000| ...
| 1 hour | 0 | 23,500,000| ...
Tablet dissolved in mouth | 6 days | 1 tablet| ... | 15,000,000
and throat gargled one | | | |
hour later | | | |
Throat again gargled two | 1 hour | 0 | ... | 10,050,000
hours after Formamint | | | |
was used | | | |
Normal | 7 days | 0 | 62,000,000| ...
Normal | 1 hour | 0 | 72,500,000| ...
Normal | ... | ... | 61,000,000| ...
Tablets were taken, one | 2 days | 12 | ... | 39,100,000
per hour, and throat | | | |
gargled onehour after | | | |
last tablet was taken | | | |
Throat was again gargled 2| 1 hour | 0 | ... | 59,000,000
hours after taking last | | | |
tablet | | | |
Normal | 5 days | 0 | 35,000,000| ...
Normal | 1 hour | 0 | 62,000,000| ...
Normal | 1 hour | 0 | 72,000,000| ...
One tablet was taken each | 4 days | 24 | ... |175,000,000
half hour for 12 hours | | tablets | |
consecutively.
Throat was| | | |
gargled one hour after | | | |
last tablet was taken | | | |
Throat was again gargled | 1 hour | 0 | ... |168,750,000
two hours after last | | | |
tablet was taken | | | |
Normal | 3 days | 0 |129,600,000| ...
Normal | 1 hour | 0 |177,000,000| ...
Normal | 1 hour | 0 |147,000,000| ...
Normal | 3 days | 0 | 79,000,000| ...
One tablet was taken | 1 hour | 1 | ... | 83,200,000
immediately after preced-| | | |
ing gargle.
Throat was | | | |
again gargled at end of | | | |
one hour | | | |
Throat was again gargled 2| 1 hour | 0 | ... |134,750,000
hours after tablet was | | | |
taken | | | |
Normal conditions except | 19 days | 0 | 32,600,000| ...
that mouth and teeth were| | | |
throughly washed with | | | |
soap just before gargling| | | |
Same as above | 1 hour | 0 | 33,125,000| ...
Same as above | 1 hour | 0 | 40,375,000| ...
Teeth were not washed. | 2 days | 0 | 33,500,000| ...
Otherwise normal con- | | | |
ditions | | | |
Same as above | 1 hour | 0 | 43,330,000| ...
Same as above | 1 hour | 0 | 54,000,000| ...
Same as above | 1 hour | 0 | 50,000,000| ...
Same as above | 1 hour | 0 | 67,000,000| ...
Mouth and teeth thoroughly| 2 days | 0 | 5,270,000| ...
washed with soap just | | | |
before throat was gargled| | | |
Same as above | 1 hour | 0 | 10,916,000| ...
Same as above | 1 hour | 0 | 8,275,000| ...
Normal conditions, but 1 | 3 days | 0 |228,750,000| ...
c.c. of sterile rabbit’s | | | |
blood was added to each | | | |
plate | | | |
Count from the same gargle| 0 | 0 | 60,625,000| ...
as above.
No blood used | | | |
in the plates | | | |
Normal conditions, but | 1 hour | 0 |431,250,000| ...
count was made on blood | | | |
agar | | | |
Count from the same gargle| 0 | 0 | 59,625,000| ...
asabove.
No blood used in| | | |
the plates | | | |
Normal conditions, count | 2 days | 0 |683,300,000| ...
was made on blood agar | | | |
Same gargle as above, but | 0 | 0 | 58,500,000| ...
count was made on plain | | | |
agar | | | |
One tablet was taken just | 1 hour | 1 tablet| ... |558,300,000
after preceding gargle. | | | |
After one hour throat was| | | |
again gargled.
Count on | | | |
blood agar | | | |
Same gargle as above, but | 0 | 1 tablet| ... | 55,875,000
count was made on plain | | | |
agar | | | |
Normal conditions | 2 days | 0 | 79,125,000| ...
One tablet was taken just | 1 hour | 1 tablet| ... | 56,250,000
ten minutes before gargle| 16 min. | | |
was made | | | |
Normal conditions | 2 days | 0 | 46,750,000| ...
One tablet was taken just | 1 hour | 1 tablet| ... | 38,500,000
ten minutes before throat| | | |
was gargled | | | |
Teeth and mouth were thor-| 5 days | 0 | 47,370,000| ...
oughly washed with soap | | | |
just before gargle was | | | |
made | | | |
Teeth washed as above and | 1 hour | 1 tablet| ... | 21,225,000
1 tablet taken 10 minutes| | | |
before gargle was made | | | |
--------------------------+---------+---------+-----------+-----------
Finally a determination was made of the number of streptococci in the throat before and after the use of Formamint. The throat was gargled in the manner previously described. The streptococcus count was made by the dilution method as given by Heinemann.[24] Culture tubes were used instead of fermentation tubes. One per cent. dextrose broth was the medium employed. One cubic centimeter was added to each of a series of ten tubes for each dilution and the following dilutions were used: 1:10,000, 1:100,000 and 1:1,000,000.
[24] Heinemann: Laboratory Guide in Bacteriology, p. 86.
The results given in Table 4 are the average count from a number of dilutions and are reported as the total number washed out by the 50 c.c. of salt solution.
TABLE 4.--SHOWING THAT FORMAMINT FAILS TO REDUCE THE NUMBER OF
STREPTOCOCCI IN THE THROAT
+===========+===========+===========+
| | | No. Found | No.
Found
| Time | Amount of | in Throat | in Throat
Conditions | Since | Formamint | Before | After
of Test | Preceding | Used | Use of | Use of
| Test | | Formamint | Formamint
--------------+-----------+-----------+-----------+----------
Normal | .... | 0 | 1,200,000 | ....
| | | |
One tablet was| | | |
taken and | | | |
throat gargled| | | |
one hour later| 4 days | 1 tablet | .... |14,750,000
| | | |
Normal | 3 days | 0 | 9,950,000 | ....
| | | |
One tablet was| | | |
taken and | | | |
throat gargled| | | |
ten minutes | | | |
later | 1 hour | 1 tablet | .... | 8,000,000
==============+===========+===========+===========+==========
Discussion
The contention that Formamint contains formaldehyd was confirmed by analysis.
The manufacturers also maintain that Formamint is a new, definite chemical compound, consisting of five molecules of formaldehyd and one molecule of lactose, and that when dissolved in the saliva the formaldehyd is liberated in some new and peculiar form, which they call nascent formaldehyd. This new kind of formaldehyd is, according to the advertising literature, especially powerful in its germicidal properties and at the same time has absolutely no irritating or harmful effects.
NOT A CHEMICAL COMPOUND
Thoms,[25] retained as an expert by the German government, decided, after a series of chemical investigations, that Formamint was not a definite chemical compound, but that it was probably a solid solution of formaldehyd in lactose. He proved that when the process of manufacture was carried out in exactly the way called for by the Formamint patents, compounds containing a greater or less per cent. of formaldehyd could be made while the other properties remained similar to those of Formamint. The composition of the final product depended on the proportion of the components used in the process. Therefore Formamint did not form a safe means of uniform dosage.
[25] Thoms: Arb. a. d. Pharm. Inst. d. Universität, Berlin =11=:210, 1914.
As a result of Thoms’ work the German courts held that Formamint was not a new chemical compound. Consequently the Formamint patent (Number
- was annulled in Berlin, Nov. 29, 1913.
Again the contention that formaldehyd in the nascent or active condition is less poisonous and irritating than in its ordinary form is contrary to what would be expected from the behavior of such compounds.
If it were liberated, as claimed, in the “nascent” condition, it would be, for that very reason, not only more active but also more harmful.
As a matter of fact, Formamint did have an irritant effect on the worker who carried out these investigations. When one tablet was taken each hour for twelve consecutive hours, marked irritation of the intestinal tract resulted. There was almost sufficient nausea to cause vomiting and uneasiness in the alimentary canal following the experiment. When the twenty-four tablets were taken the results were similar but more pronounced. This is decidedly in contradiction to the assertions of the manufacturers.
Otto Seifert,[26] moreover, cites the following:
“By Effects: Only a few patients complain of an unpleasant sharp
taste, burning of the tongue (Seifert, Sklarek). Among the general
symptoms observed are urticaria-like exanthems (Glaser, Roters),
which are accompanied by nausea, vomiting, headache, insomnia
and vertigo, burning and irritability especially in the larynx
(Meissner); phenomena of poisoning (Geissler); gastric disturbances
(Engelmann); renal irritation (Steinhard); unsuited for diabetics
(Voit).”
[26] Seifert, Otto: Die Nebenwirkungen der modernen Arzneimittel, 1915.
The contention that Formamint, when mixed directly with mediums and left in contact with bacteria, will kill the organisms was corroborated. Thus the statements and pictures in the booklet, “The Gospel of Prevention,” which is enclosed with each bottle of Formamint, showing the inhibition of growth of air bacteria on plates containing Formamint are no doubt true and authentic.
Finally, the claim that Formamint is an almost perfect throat disinfectant was by no means confirmed, as a glance at the tables will show. One hour after it is taken, even when a tablet was used each half hour for twelve hours, the number of bacteria in the throat was practically the same as when Formamint was not used. Even ten minutes after taking a tablet the number of bacteria in the throat was never greatly reduced, as is maintained by the manufacturers.
HAS NO SELECTIVE ACTION
Formamint exerts no selective action in killing off the very delicate organisms which are more apt to be pathogenic. When the comparative counts were made on blood agar which would favor the growth of the delicate parasitic organisms, no reduction whatever was shown by the use of Formamint.
The number of streptococci was found to be the same, within limits of experimental error, ten minutes after taking a tablet as it was before the tablet was taken.
Therefore it seems that Formamint fails, as any such germicide would be expected to fail, to kill bacteria in the crypts and recesses of the throat, for when dissolved in the mouth it cannot reach and remain in contact with the organisms long enough to kill them before it is swallowed.
SUMMARY
Summed up, the investigation shows:
- That the claims made for Formamint are extravagant and misleading.
- That the recommendations for the use of these tablets may be, in
some cases, fraught with danger and are a menace, not only to the health of the individual, but also to the safety of the community.
- That the claim that Formamint is a definite chemical compound is
false.
- That the use of Formamint may produce marked irritation of the
intestinal tract.
- That Formamint is not a throat disinfectant, as the manufacturers
maintain, but its action on the bacteria of the throat is an almost negligible one and dependence on Formamint for the prevention of infection and for curing disease is not only unwise but dangerous.
- That Formamint conflicts with the rules of the Council. False
statements are made with regard to its composition (Rule 1); grossly unwarranted claims are made for its therapeutic properties (Rule 6), and therefore its exploitation to the public (Rules 3 and 4) is a public danger.
It is recommended that this report be published, to call attention not only to the falsity of the claims made for, and the danger in the use of, Formamint, but also to emphasize the utter inefficiency of all such methods of “disinfecting” the throat.--(From The Journal A. M. A., Aug. 28, 1915.)
HYDRAGOGIN
Report of the Council on Pharmacy and Chemistry
Hydragogin (C. Bischoff & Co., New York, selling agents) is advertised as “a most powerful diuretic and cardiac tonic.” The composition given is:
“Fifteen parts of the remedy contain 0.5 parts oxysaponin, 1.5
parts tincture of digitalis, 2.5 parts tincture of strophanthus,
scillipicrin and scillitoxin, the active principles of scilla
maritima, and alcohol.”
It is not clear from this statement whether 15 parts of Hydragogin contain 2.5 parts of tincture of strophanthus, plus unspecified amounts of scillipicrin and scillitoxin, or 2.5 parts of a mixture, in unspecified proportions, of tincture of strophanthus, scillipicrin and scillitoxin.
The activity of strophanthus, after it enters the blood stream, is about fifty times that of digitalis; hence, if the former proportion is the true one, in giving an amount of Hydragogin which ensures the full therapeutic effect of the digitalis, one would administer an almost certainly fatal amount of strophanthus. Whatever the proportion of strophanthus may be, however, the administration of a mixture of digitalis and strophanthus in fixed proportions is indefensible.
At times it is advisable to follow one of these drugs with the other in the treatment of cardiac disease. The simultaneous administration of the two continuously in fixed proportions, however, is injudicious, because of the great difference between their rates of absorption and in their activity after they enter the blood stream. The action of digitalis, moreover, persists much longer than does that of strophanthus.
An advertising circular contains the following claim:
“The well-known diuretic properties of digitalis, strophanthus and
squills are greatly enhanced by the addition of the oxysaponin.”
This is not true. Saponins are not synergistic with digitalis therapeutically; on the contrary, they exert a purely deleterious action on the heart when they enter the circulation.
The symptoms of cardiac disease are often difficult to distinguish from the toxic actions of the digitalis bodies. Since these bodies must often be given to the point of beginning toxic action in order to induce the full therapeutic effects, it is obvious that the administration of a mixture of digitalis, strophanthus, saponin and active principles of squill is especially liable to induce serious toxic effects which cannot be distinguished from the symptoms of the disease.
Hydragogin is a shotgun mixture of semisecret composition; it is marketed under a therapeutically suggestive name, and advertised by means of unwarranted therapeutic claims. It is therefore in conflict with Rules 1, 6, 8 and 10. The Council held Hydragogin ineligible for New and Nonofficial Remedies.--(From The Journal A. M. A., Sept. 4, 1915.)
FILUDINE
Report of the Council on Pharmacy and Chemistry
Filudine is said to be prepared by J. L. Chatelain, Paris, and is sold in this country by Geo. J. Wallau, Inc., New York. It is offered as a remedy for “biliary insufficiency,” “hepatic insufficiency,” “intestinal dyspepsia,” “all affections of the liver (diabetes, cirrhosis, cancer, etc.),” “malaria,” “obesity” and “tuberculosis.”
No quantitative information is furnished as to the composition of the preparation and there are noteworthy discrepancies in the various statements regarding the ingredients. In one number of “Treatment,” a self-styled “Review” of medical literature (actually devoted to advertising the preparations sold by Wallau), we are told that
“This product [Filudine] is a more concentrated and potent extract
of the liver, with which is combined an extract of the spleen. The
liver and the spleen are so intimately interdependent, that the
addition of a splenary extract to the liver extract is a signal
improvement from which a synergistic action results. Thiarféine is
also added, as it helps somewhat to combat the anaemia from which
all diabetics suffer more or less.”
Thiarféine is said to be
“Thiomethylarsinate of Caffein, a new salt discovered by M.
Chatelain.”
Another circular, which gives an imposing formula for “thiarféine” or “thiomethylarsinate of caffein,” states that
“Sulphurated methylarsinate is an arsenical preparation devoid of
all toxicity on account of the intimate joining of its composing
parts.”
And that
“Filudine can never be contraindicated.”
A statement of composition in a later number of “Treatment,” however, says that biliary extracts are components, in addition to the liver and spleen extracts. Moreover, thiarféine, the “new salt discovered by M.
Chatelain,” is no longer “thiomethylarsinate,” but “thiocinnamate of caffein”; and a new formula is furnished for it.
We are told that
“Methyl-arsinate cannot be used in cases where fever is present....”
“M. Chatelain at first studied the action of thiomethylarsinate;
clinical and physiological experimentation led him, however, to
adopt thiocinnamate of caffein, of greater activity and with no
contraindications.”
Nevertheless the same absence of contraindications was urged in favor of Filudine when it was said to contain the now discarded thiomethylarsinate of caffein.
The following are some of the unwarranted and even absurd claims:
“Filudine restores the liver’s functions. It is to the liver what
digitalis is to the heart; it overcomes the insufficiency and
stimulates the debilitated organ.”
In malaria “it is the only true specific when associated with
quinine.”
“Filudine is ... the ideal medication for tuberculosis, conforming
as it does with the most recent researches in the therapeusis of
this affection.”
“We will not go as far as to say that Opotherapy completely
restores unhealthy livers, for although the lesions of the hepatic
parenchyma may be obliterated by regeneration, the lesions of
the connective tissues are permanent, and may be observed at the
postmortem examination. The new cells, however, do not present the
same unhealthy conditions as those of the former diseased gland
which they have replaced, and the liver can therefore function
normally, so that the patient lives on; and he is satisfied with
that.”
“Therefore, while regenerating the liver with Filudine, we cleanse
it and combat its congested state with Urodonal. We cause it to
produce urea from the excess of uric acid which it contains.”
“By the judicious and harmonious combination of the beneficial
effects of Filudine and Urodonal, physicians not only possess the
means of treating by rational methods Cirrhosis of the Liver in its
various forms (which is one of the most terrible diseases which can
afflict anyone) but what is still better, they can cure it.”
“The liver of a person suffering from obesity being incapable
of fulfilling its functions in regard to the fatty tissues, the
rational and up-to-date method of treatment is therefore to restore
to the system, in the form of Filudine, the liver extracts which
are lacking.”
Filudine is a mixture of semisecret composition. The therapeutic claims are manifestly unwarranted. The name is not indicative of the composition, whatever that may be, and no rational excuse is offered for the combination of liver and spleen extracts (with or without bile extracts) with “thiomethylarsinate” or “thiocinnamate” of caffein.
The Council therefore held Filudine ineligible for New and Nonofficial Remedies.--(From The Journal A. M. A., Sept. 18, 1915.)
LACTOPEPTINE AND ELIXIR LACTOPEPTINE
Report of the Council on Pharmacy and Chemistry
Mixtures of pepsin and pancreatin are therapeutically irrational; the two substances are not indicated in the same conditions, nor can they act together. Under physiologic conditions, such mixtures are chemically impossible: in a liquid medium the ingredients destroy each other.
Lactopeptin is manufactured by the New York Pharmacal Association, Yonkers, N. Y. It is sold under the claim that it contains, pepsin, diastase, pancreatin, lactic acid and hydrochloric acid. This product was among the first proprietary preparations examined by the Council on Pharmacy and Chemistry. The report of the investigation was published in The Journal, March 16, 1907, p. 959. The preparation was found to be practically inert--“essentially a weak saccharated pepsin,” devoid of tryptic activity.
Six years later it was still widely advertised with the same irrational claims. A referee (A) therefore examined Lactopeptine (powdered) for the Council in 1913, and confirmed the previous findings. The referee’s report was published in The Journal, Aug. 2, 1913, p. 358.
Nearly four months after this publication, the manufacturer protested against the report, maintaining, contrary to the findings of the Council, that Lactopeptine possesses pancreatic activity and contains “loosely combined” hydrochloric acid. Referee A therefore repeated his examination, and a second referee (B), independently, examined specimens of Lactopeptine (powder) purchased on the open market for the purpose shortly before.
A few specimens examined by these two referees showed a slight tryptic activity; most of them showed none. The amount of hydrochloric acid present was insignificant.
The reports of the two referees were referred to the manufacturers, who again protested vehemently against these findings, this time on the ground that the specimens were old. The manufacturers also cited the work of three chemists to disprove the findings of the referees, and demanded that the Council reexamine Lactopeptine, making use of fresh specimens. The Council refused for the following reasons:
- So long as the packages of Lactopeptine are not dated, the activity
of specimens known to be fresh is of no practical importance. The activity of the actual market supply is the only question of interest to the profession. The only fair test is that made on specimens representative of the product sold to the ultimate consumer.
- The evidence presented by the manufacturers did not warrant
a reexamination, since the work of two of the chemists cited substantially corroborates the results obtained by the Council’s referees from the fresher specimens. The figures for tryptic activity obtained by the third chemist cited by the manufacturers could not be accepted by the Council, since it was at variance with all other known results of investigations of Lactopeptine.
- As stated at the outset, whatever the tryptic activity of the
mixture, it is therapeutically useless. A demonstration of tryptic activity in a mixture containing both pepsin and pancreatin is of merely theoretical interest.
Such activity, of course, cannot be expected, even on theoretical grounds, in liquid mixtures like Elixir Lactopeptine.
The Council therefore again declared Lactopeptine (powder and tablets) and Elixir Lactopeptine ineligible for New and Nonofficial Remedies and authorized publication of the following statement.
W. A. Puckner, Secretary
THE COUNCIL’S REPORT
Lactopeptine powder (New York Pharmacal Association, Yonkers, N. Y.) was examined by the Council in 1907. At that time it was claimed to contain
“... the five active agents of digestion--pepsin, diastase (veg.
ptyalin), pancreatin, lactic acid and hydrochloric acid--combined
in the proper proportion to insure the best results.”
The examination showed that the preparation was essentially “a weak saccharated pepsin,” containing but small amounts of pepsin, no hydrochloric acid, or mere traces only, and no diastase or pancreatin (The Journal, March 16, 1907).
In 1913, the product was reexamined, because the claims, as to both composition and therapeutic value, were still being made. Samples were tested both of the American product, and of a British product from John Morgan Richards & Sons, London. The original findings were confirmed and the results were published in The Journal, Aug. 2, 1913, p. 358. Nearly four months later (November 24) the New York Pharmacal Association wrote to the Council, objecting to the findings and maintaining that Lactopeptine possesses pancreatic activity and contains (“in loose chemical combination”) hydrochloric acid.
In accordance with the custom of the Council, the work was sent back for review to the referee (A), whose conclusions were then tested by a second referee (B), a phy
Edition notice Project Gutenberg source, credits & licence
The reading text above is the public-domain work. The Project Gutenberg header, production credits and licence are kept here as provenance rather than shown before the book.
Transcriber and production notes
Transcriber’s notes:
Front matter as received (title page, contents)
In this transcription, paired _underscores_ denote _italicised
text_ and a ^ indicates a superscripted character. A downward arrow
preceding curly brackets indicates that the bracketed character(s) are
subscripted, e.g. ↓{H}.
The text contains some uncommon characters that will not necessarily
display correctly with all viewing devices. If some of the characters
look abnormal, first ensure that the device’s character encoding is
set to Unicode (UTF-8). The default font might also need to be changed
to a Unicode font such as Arial Unicode MS, DejaVu, Segoe UI Symbol or
FreeSerif. Symbols representing male and female have been replaced by M
and F in the handheld version. Subscripted and superscripted characters
do not always display correctly on handheld devices.
The book contained innumerable typographical errors affecting spelling,
punctuation and formatting. Most spelling errors have been corrected
silently, but spelling variants that mainly reflect contemporary
spellings in the original quoted sources, have been left unchanged. A
list of the corrections and variations can be seen at the end of the
transcription. Punctuation anomalies (errors, omissions, duplications)
have mostly been corrected silently, but missing apostrophes have not
been corrected because of uncertainty about intended meaning. A few
missing quotation marks have been inserted within curly brackets {"}
and missing words inserted by the transcriber, e.g. {sic} {and} have
also been enclosed within curly brackets to differentiate them from
the numerous words and phrases inserted by the authors. Redundant
duplicated words have been deleted. Astute readers will probably note
persisting inconsistencies involving italics, fonts, hyphenation,
ellipses, accents, and ligatures (ae/æ, oe/œ) that have been left
unchanged because they have no impact on interpretation of the text.
The Table of Contents does not correspond accurately with headings used
in the text.
Footnotes are generally located below the relevant paragraphs;
however, footnotes that are cross-referenced multiple times
have not been duplicated. An error in footnote numbering
was corrected silently, and a missing footnote [120] was
inserted after being identified in the original source.
Over-sized tables have been compressed and where appropriate a key has
been inserted to assist the reader.
THE PROPAGANDA FOR REFORM
IN
Proprietary Medicines
VOLUME 2
Part I Reports of the Council
Part II Contributions from the Laboratory
Part III Journal Contributions: Proprietary Products
Part IV Journal Contributions: Miscellany
PRESS OF AMERICAN MEDICAL ASSOCIATION, FIVE HUNDRED AND THIRTY-FIVE
NORTH DEARBORN STREET,--CHICAGO
1922
COPYRIGHT, 1922 BY THE AMERICAN MEDICAL ASSOCIATION
PREFACE TO VOLUME 2
There were nine editions of the first volume of The Propaganda for
Reform in Proprietary Medicines. The ninth edition contained the most
important reports of the Council on Pharmacy and Chemistry and of the
Chemical Laboratory. It contained also those articles from _The Journal
of the American Medical Association_ (up to, and including, 1916)
which dealt with the problems of proprietaryship in medicine and the
furtherance of rational drug therapy.
The present volume contains similar material covering the period from
January, 1917, to April, 1922, inclusive. Like Volume 1, this volume is
divided into four parts:Header as received
The Project Gutenberg eBook of The Propaganda for Reform in Proprietary Medicines, Vol. 2 of 2
This eBook is for the use of anyone anywhere in the United States and
most other parts of the world at no cost and with almost no restrictions
whatsoever. You may copy it, give it away or re-use it under the terms
of the Project Gutenberg License included with this eBook or online
at www.gutenberg.org. If you are not located in the United States,
you will have to check the laws of the country where you are located
before using this eBook.
Title: The Propaganda for Reform in Proprietary Medicines, Vol. 2 of 2
Author: Council on Pharmacy and Chemistry
Release date: December 24, 2014 [eBook #47767]
Most recently updated: October 24, 2024
Language: English
Other information and formats: www.gutenberg.org/ebooks/47767
Credits: Produced by David Edwards, Thiers Halliwell and the Online
Distributed Proofreading Team at http://www.pgdp.net (This
file was produced from images generously made available
by The Internet Archive)Full Project Gutenberg licence
Updated editions will replace the previous one—the old editions will
be renamed.
Creating the works from print editions not protected by U.S. copyright
law means that no one owns a United States copyright in these works,
so the Foundation (and you!) can copy and distribute it in the United
States without permission and without paying copyright
royalties. Special rules, set forth in the General Terms of Use part
of this license, apply to copying and distributing Project
Gutenberg™ electronic works to protect the PROJECT GUTENBERG™
concept and trademark. Project Gutenberg is a registered trademark,
and may not be used if you charge for an eBook, except by following
the terms of the trademark license, including paying royalties for use
of the Project Gutenberg trademark. If you do not charge anything for
copies of this eBook, complying with the trademark license is very
easy. You may use this eBook for nearly any purpose such as creation
of derivative works, reports, performances and research. Project
Gutenberg eBooks may be modified and printed and given away—you may
do practically ANYTHING in the United States with eBooks not protected
by U.S. copyright law. Redistribution is subject to the trademark
license, especially commercial redistribution.
START: FULL LICENSE
THE FULL PROJECT GUTENBERG™ LICENSE
PLEASE READ THIS BEFORE YOU DISTRIBUTE OR USE THIS WORK
To protect the Project Gutenberg™ mission of promoting the free
distribution of electronic works, by using or distributing this work
(or any other work associated in any way with the phrase “Project
Gutenberg”), you agree to comply with all the terms of the Full
Project Gutenberg License available with this file or online at
www.gutenberg.org/license.
Section 1. General Terms of Use and Redistributing Project Gutenberg
electronic works
1.A. By reading or using any part of this Project Gutenberg
electronic work, you indicate that you have read, understand, agree to
and accept all the terms of this license and intellectual property
(trademark/copyright) agreement. If you do not agree to abide by all
the terms of this agreement, you must cease using and return or
destroy all copies of Project Gutenberg electronic works in your
possession. If you paid a fee for obtaining a copy of or access to a
Project Gutenberg electronic work and you do not agree to be bound
by the terms of this agreement, you may obtain a refund from the person
or entity to whom you paid the fee as set forth in paragraph 1.E.8.
1.B. “Project Gutenberg” is a registered trademark. It may only be
used on or associated in any way with an electronic work by people who
agree to be bound by the terms of this agreement. There are a few
things that you can do with most Project Gutenberg electronic works
even without complying with the full terms of this agreement. See
paragraph 1.C below. There are a lot of things you can do with Project
Gutenberg electronic works if you follow the terms of this
agreement and help preserve free future access to Project Gutenberg
electronic works. See paragraph 1.E below.
1.C. The Project Gutenberg Literary Archive Foundation (“the
Foundation” or PGLAF), owns a compilation copyright in the collection
of Project Gutenberg electronic works. Nearly all the individual
works in the collection are in the public domain in the United
States. If an individual work is unprotected by copyright law in the
United States and you are located in the United States, we do not
claim a right to prevent you from copying, distributing, performing,
displaying or creating derivative works based on the work as long as
all references to Project Gutenberg are removed. Of course, we hope
that you will support the Project Gutenberg mission of promoting
free access to electronic works by freely sharing Project Gutenberg
works in compliance with the terms of this agreement for keeping the
Project Gutenberg name associated with the work. You can easily
comply with the terms of this agreement by keeping this work in the
same format with its attached full Project Gutenberg License when
you share it without charge with others.
1.D. The copyright laws of the place where you are located also govern
what you can do with this work. Copyright laws in most countries are
in a constant state of change. If you are outside the United States,
check the laws of your country in addition to the terms of this
agreement before downloading, copying, displaying, performing,
distributing or creating derivative works based on this work or any
other Project Gutenberg work. The Foundation makes no
representations concerning the copyright status of any work in any
country other than the United States.
1.E. Unless you have removed all references to Project Gutenberg:
1.E.1. The following sentence, with active links to, or other
immediate access to, the full Project Gutenberg License must appear
prominently whenever any copy of a Project Gutenberg work (any work
on which the phrase “Project Gutenberg” appears, or with which the
phrase “Project Gutenberg” is associated) is accessed, displayed,
performed, viewed, copied or distributed:
This eBook is for the use of anyone anywhere in the United States and most
other parts of the world at no cost and with almost no restrictions
whatsoever. You may copy it, give it away or re-use it under the terms
of the Project Gutenberg™ License included with this eBook or online
at www.gutenberg.org. If you
are not located in the United States, you will have to check the laws
of the country where you are located before using this eBook.
1.E.2. If an individual Project Gutenberg electronic work is
derived from texts not protected by U.S. copyright law (does not
contain a notice indicating that it is posted with permission of the
copyright holder), the work can be copied and distributed to anyone in
the United States without paying any fees or charges. If you are
redistributing or providing access to a work with the phrase “Project
Gutenberg” associated with or appearing on the work, you must comply
either with the requirements of paragraphs 1.E.1 through 1.E.7 or
obtain permission for the use of the work and the Project Gutenberg
trademark as set forth in paragraphs 1.E.8 or 1.E.9.
1.E.3. If an individual Project Gutenberg electronic work is posted
with the permission of the copyright holder, your use and distribution
must comply with both paragraphs 1.E.1 through 1.E.7 and any
additional terms imposed by the copyright holder. Additional terms
will be linked to the Project Gutenberg License for all works
posted with the permission of the copyright holder found at the
beginning of this work.
1.E.4. Do not unlink or detach or remove the full Project Gutenberg
License terms from this work, or any files containing a part of this
work or any other work associated with Project Gutenberg.
1.E.5. Do not copy, display, perform, distribute or redistribute this
electronic work, or any part of this electronic work, without
prominently displaying the sentence set forth in paragraph 1.E.1 with
active links or immediate access to the full terms of the Project
Gutenberg License.
1.E.6. You may convert to and distribute this work in any binary,
compressed, marked up, nonproprietary or proprietary form, including
any word processing or hypertext form. However, if you provide access
to or distribute copies of a Project Gutenberg work in a format
other than “Plain Vanilla ASCII” or other format used in the official
version posted on the official Project Gutenberg website
(www.gutenberg.org), you must, at no additional cost, fee or expense
to the user, provide a copy, a means of exporting a copy, or a means
of obtaining a copy upon request, of the work in its original “Plain
Vanilla ASCII” or other form. Any alternate format must include the
full Project Gutenberg License as specified in paragraph 1.E.1.
1.E.7. Do not charge a fee for access to, viewing, displaying,
performing, copying or distributing any Project Gutenberg works
unless you comply with paragraph 1.E.8 or 1.E.9.
1.E.8. You may charge a reasonable fee for copies of or providing
access to or distributing Project Gutenberg electronic works
provided that:
• You pay a royalty fee of 20% of the gross profits you derive from
the use of Project Gutenberg works calculated using the method
you already use to calculate your applicable taxes. The fee is owed
to the owner of the Project Gutenberg trademark, but he has
agreed to donate royalties under this paragraph to the Project
Gutenberg Literary Archive Foundation. Royalty payments must be paid
within 60 days following each date on which you prepare (or are
legally required to prepare) your periodic tax returns. Royalty
payments should be clearly marked as such and sent to the Project
Gutenberg Literary Archive Foundation at the address specified in
Section 4, “Information about donations to the Project Gutenberg
Literary Archive Foundation.”
• You provide a full refund of any money paid by a user who notifies
you in writing (or by e-mail) within 30 days of receipt that s/he
does not agree to the terms of the full Project Gutenberg™
License. You must require such a user to return or destroy all
copies of the works possessed in a physical medium and discontinue
all use of and all access to other copies of Project Gutenberg™
works.
• You provide, in accordance with paragraph 1.F.3, a full refund of
any money paid for a work or a replacement copy, if a defect in the
electronic work is discovered and reported to you within 90 days of
receipt of the work.
• You comply with all other terms of this agreement for free
distribution of Project Gutenberg™ works.
1.E.9. If you wish to charge a fee or distribute a Project
Gutenberg™ electronic work or group of works on different terms than
are set forth in this agreement, you must obtain permission in writing
from the Project Gutenberg Literary Archive Foundation, the manager of
the Project Gutenberg™ trademark. Contact the Foundation as set
forth in Section 3 below.
1.F.
1.F.1. Project Gutenberg volunteers and employees expend considerable
effort to identify, do copyright research on, transcribe and proofread
works not protected by U.S. copyright law in creating the Project
Gutenberg™ collection. Despite these efforts, Project Gutenberg™
electronic works, and the medium on which they may be stored, may
contain “Defects,” such as, but not limited to, incomplete, inaccurate
or corrupt data, transcription errors, a copyright or other
intellectual property infringement, a defective or damaged disk or
other medium, a computer virus, or computer codes that damage or
cannot be read by your equipment.
1.F.2. LIMITED WARRANTY, DISCLAIMER OF DAMAGES - Except for the “Right
of Replacement or Refund” described in paragraph 1.F.3, the Project
Gutenberg Literary Archive Foundation, the owner of the Project
Gutenberg™ trademark, and any other party distributing a Project
Gutenberg™ electronic work under this agreement, disclaim all
liability to you for damages, costs and expenses, including legal
fees. YOU AGREE THAT YOU HAVE NO REMEDIES FOR NEGLIGENCE, STRICT
LIABILITY, BREACH OF WARRANTY OR BREACH OF CONTRACT EXCEPT THOSE
PROVIDED IN PARAGRAPH 1.F.3. YOU AGREE THAT THE FOUNDATION, THE
TRADEMARK OWNER, AND ANY DISTRIBUTOR UNDER THIS AGREEMENT WILL NOT BE
LIABLE TO YOU FOR ACTUAL, DIRECT, INDIRECT, CONSEQUENTIAL, PUNITIVE OR
INCIDENTAL DAMAGES EVEN IF YOU GIVE NOTICE OF THE POSSIBILITY OF SUCH
DAMAGE.
1.F.3. LIMITED RIGHT OF REPLACEMENT OR REFUND - If you discover a
defect in this electronic work within 90 days of receiving it, you can
receive a refund of the money (if any) you paid for it by sending a
written explanation to the person you received the work from. If you
received the work on a physical medium, you must return the medium
with your written explanation. The person or entity that provided you
with the defective work may elect to provide a replacement copy in
lieu of a refund. If you received the work electronically, the person
or entity providing it to you may choose to give you a second
opportunity to receive the work electronically in lieu of a refund. If
the second copy is also defective, you may demand a refund in writing
without further opportunities to fix the problem.
1.F.4. Except for the limited right of replacement or refund set forth
in paragraph 1.F.3, this work is provided to you ‘AS-IS’, WITH NO
OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT
LIMITED TO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PURPOSE.
1.F.5. Some states do not allow disclaimers of certain implied
warranties or the exclusion or limitation of certain types of
damages. If any disclaimer or limitation set forth in this agreement
violates the law of the state applicable to this agreement, the
agreement shall be interpreted to make the maximum disclaimer or
limitation permitted by the applicable state law. The invalidity or
unenforceability of any provision of this agreement shall not void the
remaining provisions.
1.F.6. INDEMNITY - You agree to indemnify and hold the Foundation, the
trademark owner, any agent or employee of the Foundation, anyone
providing copies of Project Gutenberg™ electronic works in
accordance with this agreement, and any volunteers associated with the
production, promotion and distribution of Project Gutenberg™
electronic works, harmless from all liability, costs and expenses,
including legal fees, that arise directly or indirectly from any of
the following which you do or cause to occur: (a) distribution of this
or any Project Gutenberg work, (b) alteration, modification, or
additions or deletions to any Project Gutenberg work, and (c) any
Defect you cause.
Section 2. Information about the Mission of Project Gutenberg
Project Gutenberg is synonymous with the free distribution of
electronic works in formats readable by the widest variety of
computers including obsolete, old, middle-aged and new computers. It
exists because of the efforts of hundreds of volunteers and donations
from people in all walks of life.
Volunteers and financial support to provide volunteers with the
assistance they need are critical to reaching Project Gutenberg’s
goals and ensuring that the Project Gutenberg collection will
remain freely available for generations to come. In 2001, the Project
Gutenberg Literary Archive Foundation was created to provide a secure
and permanent future for Project Gutenberg and future
generations. To learn more about the Project Gutenberg Literary
Archive Foundation and how your efforts and donations can help, see
Sections 3 and 4 and the Foundation information page at www.gutenberg.org.
Section 3. Information about the Project Gutenberg Literary Archive Foundation
The Project Gutenberg Literary Archive Foundation is a non-profit
501(c)(3) educational corporation organized under the laws of the
state of Mississippi and granted tax exempt status by the Internal
Revenue Service. The Foundation’s EIN or federal tax identification
number is 64-6221541. Contributions to the Project Gutenberg Literary
Archive Foundation are tax deductible to the full extent permitted by
U.S. federal laws and your state’s laws.
The Foundation’s business office is located at 41 Watchung Plaza #516,
Montclair NJ 07042, USA, +1 (862) 621-9288. Email contact links and up
to date contact information can be found at the Foundation’s website
and official page at www.gutenberg.org/contact
Section 4. Information about Donations to the Project Gutenberg
Literary Archive Foundation
Project Gutenberg™ depends upon and cannot survive without widespread
public support and donations to carry out its mission of
increasing the number of public domain and licensed works that can be
freely distributed in machine-readable form accessible by the widest
array of equipment including outdated equipment. Many small donations
($1 to $5,000) are particularly important to maintaining tax exempt
status with the IRS.
The Foundation is committed to complying with the laws regulating
charities and charitable donations in all 50 states of the United
States. Compliance requirements are not uniform and it takes a
considerable effort, much paperwork and many fees to meet and keep up
with these requirements. We do not solicit donations in locations
where we have not received written confirmation of compliance. To SEND
DONATIONS or determine the status of compliance for any particular state
visit www.gutenberg.org/donate.
While we cannot and do not solicit contributions from states where we
have not met the solicitation requirements, we know of no prohibition
against accepting unsolicited donations from donors in such states who
approach us with offers to donate.
International donations are gratefully accepted, but we cannot make
any statements concerning tax treatment of donations received from
outside the United States. U.S. laws alone swamp our small staff.
Please check the Project Gutenberg web pages for current donation
methods and addresses. Donations are accepted in a number of other
ways including checks, online payments and credit card donations. To
donate, please visit: www.gutenberg.org/donate.
Section 5. General Information About Project Gutenberg electronic works
Professor Michael S. Hart was the originator of the Project
Gutenberg concept of a library of electronic works that could be
freely shared with anyone. For forty years, he produced and
distributed Project Gutenberg eBooks with only a loose network of
volunteer support.
Project Gutenberg eBooks are often created from several printed
editions, all of which are confirmed as not protected by copyright in
the U.S. unless a copyright notice is included. Thus, we do not
necessarily keep eBooks in compliance with any particular paper
edition.
Most people start at our website which has the main PG search
facility: www.gutenberg.org.
This website includes information about Project Gutenberg,
including how to make donations to the Project Gutenberg Literary
Archive Foundation, how to help produce our new eBooks, and how to
subscribe to our email newsletter to hear about new eBooks.Source: Project Gutenberg ebook #47767. Public-domain status is recorded per item; the licence text above is reproduced unchanged.